# Innovations in Pharmaceutical Therapeutics and Drug Delivery

Dr. A. RAMYA
Mrs. R. PRASIDHA
Dr. VIJAYAKUMAR MURUGESAN
Dr. KOMMU PRADEEP

SRR
Publicizing Research

ISBN 978-816855388-0

# Innovations in Pharmaceutical Therapeutics and Drug Delivery

April 2026


**Dr. A. RAMYA**
Assistant Professor, Department of Pharmacology
School of Pharmaceutical Sciences
Vels Institute of Science, Technology & Advanced Studies (VISTAS), Chennai, Tamil Nadu, India.

**Mrs. R. PRASIDHA**
Assistant Professor
Department of Pharmaceutical Chemistry and Analysis
School of Pharmaceutical Sciences
Vels Institute of Science, Technology & Advanced Studies (VISTAS), Chennai, Tamil Nadu, India.

**Dr. VIJAYAKUMAR MURUGESAN**
Department of Pharmaceutics, School of Pharmacy
JSS Academy of Higher Education and Research
Mauritius.

**Dr. KOMMU PRADEEP**
Assistant Professor
Faculty of Health Sciences
Villa College, Maldives.

**April 2026**

**ISBN: 978-81-685538-8-0**

ISBN 978-816855388-0



**Published By**

SRR
Publicizing Research

**SCIENTIFIC RESEARCH REPORTS**
**(A Book Publisher, approved by Govt. of India)**

**I Floor, S S Nagar, Chennai - 600 087,**
**Tamil Nadu, India.**

**editors@srrbooks.in, contact@srrbooks.in**
**www.srrbooks.in**

# PREFACE

The expanding frontiers of pharmaceutical therapeutics and drug delivery are redefining the landscape of modern medicine, integrating molecular insights, advanced nanotechnology, and evidence-based clinical strategies. *Innovations in Pharmaceutical Therapeutics and Drug Delivery* presents a comprehensive exploration of these developments, highlighting the convergence of interdisciplinary approaches that address complex diseases and unmet clinical needs.

A prominent focus of this volume lies in the advancement of nanotechnology-driven drug delivery systems, particularly in overcoming biological barriers such as the blood–brain barrier (BBB). Innovative strategies, including redox-responsive liposomal systems and nanoparticle-based carriers, demonstrate significant potential in enhancing drug targeting, improving therapeutic efficacy, and minimizing systemic toxicity. These approaches are especially critical in the management of neurodegenerative disorders, where precise delivery and modulation of oxidative stress and neuroinflammation are essential.

The book also emphasizes the role of molecular and genetic factors in disease pathogenesis and therapeutic outcomes. Chapters addressing monogenic disorders, calcium metabolism polymorphisms, and genetic predisposition in kidney stone disease underscore the importance of personalized medicine. By understanding individual variability at the genetic level, more effective prevention and treatment strategies can be developed, particularly in recurrent and chronic conditions.

Another key theme is the identification and application of biomarkers for early disease detection and prognosis. The exploration of biomarkers in renal injury highlights their clinical significance in enabling timely intervention and improving patient outcomes. Complementing this, pharmacological strategies for the prevention of recurrent kidney stones and evidence-based approaches such as medical expulsive therapy illustrate the integration of research findings into clinical practice.

The volume further extends into the study of endocrine and metabolic disorders, with discussions on hypercortisolism and calcium homeostasis, as well as broader physiological systems such as liver function. These chapters provide a pathophysiological foundation that bridges biological understanding with therapeutic innovation, reinforcing the importance of holistic approaches in drug development.

Infectious diseases and their evolving therapeutic challenges are also addressed, particularly through the study of viral evolution and modern treatment strategies. Such insights are vital in preparing for future pandemics and improving current antiviral interventions. Additionally, rare genetic conditions, including Fragile X syndrome, are examined to shed light on their complex etiology and management, further broadening the scope of therapeutic research.

The inclusion of emerging technologies such as nanorobots signifies the future trajectory of drug delivery, where precision, automation, and targeted intervention converge. These innovations hold the promise of revolutionizing treatment modalities across a wide range of diseases.

We extend our sincere thanks to our publisher, Scientific Research Reports, Chennai, India, for their dedicated efforts in preparing this book and for ensuring the inclusion of enriched and high-quality technical content.

*Wishes and Regards,*

**Dr. A. RAMYA**
Assistant Professor
Department of Pharmacology
School of Pharmaceutical Sciences
Vels Institute of Science, Technology & Advanced Studies (VISTAS),
Chennai, Tamil Nadu, India.

**Mrs. R. PRASIDHA**
Assistant Professor
Department of Pharmaceutical Chemistry and Analysis
School of Pharmaceutical Sciences
Vels Institute of Science, Technology & Advanced Studies (VISTAS),
Chennai, Tamil Nadu, India.

**Dr. VIJAYAKUMAR MURUGESAN**
Department of Pharmaceutics
School of Pharmacy
JSS Academy of Higher Education and Research, Mauritius.

**Dr. KOMMU PRADEEP**
Assistant Professor
Faculty of Health Sciences
Villa College, Maldives.

# CONTENTS


SRR
Publicizing Research

# Chapter 1

# Redox-responsive Liposomal co-delivery of taxifolin and galantamine for restoration of BBB Integrity and Attenuation of Oxidative Neuroinflammation in Aβ-Induced Neurodegenerative Rats

**Aafila Simana[a], Abdul basith[b], C.Ronald Darwin[b*]**

[a]*B.Pharm student, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advance Studies, Chennai.*

[b]*Professor and Head, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advance Studies, Chennai.*

** Corresponding Author: hodpcology.sps@vistas.ac.in*

**Abstract**

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by amyloid-β aggregation, oxidative stress, neuroinflammation, cholinergic dysfunction, and blood–brain barrier (BBB) disruption. The present study proposes a redox-responsive liposomal co-delivery system encapsulating Taxifolin and Galantamine for synergistic AD management. Taxifolin provides antioxidant, anti-amyloidogenic, and anti-inflammatory effects, while Galantamine enhances cholinergic neurotransmission through acetylcholinesterase inhibition and nicotinic receptor modulation. The liposomes were characterized for particle size, zeta potential, encapsulation efficiency, and in vitro redox-triggered drug release. Pharmacokinetic evaluation suggests improved bioavailability, prolonged systemic circulation, protection from premature metabolism, and enhanced BBB penetration following intravenous

ISBN 978-816855388-0

administration. Upon exposure to oxidative conditions, the formulation enables controlled drug release at the pathological site. Pharmacodynamically, the system reduces reactive oxygen species, suppresses pro-inflammatory cytokines, inhibits amyloid aggregation, restores tight junction protein integrity, and improves cholinergic signaling. This dual-targeted nanoformulation represents a promising disease-modifying strategy integrating neuroprotection with symptomatic improvement in Alzheimer's disease.

*Keywords: Alzheimer's disease, Amyloid-ß aggregation, Redox-responsive liposomes, Toxifolin, Galantamine, Blood brain barrier(BBB).*

## 1. Introduction

A small liposomal co delivery system that releases Taxifolin and Galantamine only in the area of high oxidative stress in brain, to repair Blood-brain barrier damage and reduce the neuro inflammation caused by Amyloid -beta protein. In this poster, we focus on a targeted therapeutic system for Alzheimer's disease using a redox-responsive liposomal system. Basically, Alzheimer's disease is a chronic neurodegenarative disorder which is charecterized by memory loss, behaviour disturbance. One of the most important pathological features in Alzheimer's Disease is accumulation of amyloid beta protein in the brain.[1]

## 2. Etiology

Amyloid plaques (also known as neuritic plaques, amyloid beta plaques or senile plaques) are extracellular deposits of amyloid beta (Aβ) protein that present mainly in the grey matter of the brain[2][3][4][5]. Degenerative neuronal elements and an abundance of microglia and astrocytes can be associated with amyloid plaques.

Some plaques occur in the brain as a result of aging, but large numbers of plaques and neurofibrillary tangles are characteristic features of Alzheimer's disease. The major cause is abnormal accumulation of β-amyloid peptides due to improper cleavage of amyloid precursor protein (APP), leading to formation of extracellular amyloid plaques in the brain. Another key factor is hyperphosphorylation of tau protein, which results in intracellular neurofibrillary tangles and neuronal degeneration. Genetic mutations in APP, presenilin-1 (PSEN1), and presenilin-2 (PSEN2) are associated with early-onset familial cases, while the ApoE-ε4 allele is a major risk factor for late-onset disease. In addition, cholinergic neuron degeneration causing decreased acetylcholine levels, oxidative stress, neuroinflammation, aging, head injury, and cardiovascular conditions such as hypertension and diabetes also contribute to the development of the disease. [6]

**3. Current treatment**

Over the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with Alzheimer's disease has increased. Although these pharmacological and non-pharmacological strategies have significantly improved health outcomes for patients with Alzheimer's disease, many lack stringent evidence of efficacy[7]. In Alzheimer's disease, the drugs currently used mainly help in improving symptoms or slowing disease progression. Acetylcholinesterase inhibitors such as Donepezil, Taxifolin and Galantamine increase acetylcholine levels in the brain and are used in mild to moderate stages. Memantine, an NMDA receptor antagonist, is used in moderate to severe cases to reduce glutamate-mediated excitotoxicity. Recently, disease-modifying

ISBN 978-816855388-0

monoclonal antibodies like Lecanemab and Donanemab have been introduced to target amyloid-beta plaques and help slow disease progression in early stages [8].

**4. Combination therapy**

Combination therapy is a treatment approach in which two or more drugs are used together to treat a single disease. The drugs may have different mechanisms of action, and when used together, they can produce a better therapeutic effect than a single drug alone. Although there are several drugs available for Alzheimer's treatment, most of them only provide symptomatic relief. They do not effectively address oxidative stress, neuroinflammation and Blood Brain Barrier damage simultaneously[9]. Moreover, drug delivery to Blood Brain Barrier is difficult due it's restrective nature. Here there is a need of a targeted drug delivery system with a multi-targeted therapeutic approach. And a system that releases the drug specifically in diseased region. This is where liposomal co-drug delivery system occurs. It is basically designed as the redox response liposomal co drug delivery systems releases the drugs only when there is high oxidative stress occurs. The concept is, when the liposomes reaches the region with high reactive oxygen species it breaks down and releases the drugs specifically there. This ensures that, the targeted drug delivery system and improved therapeutic efficiency [10].

**5. Galantamine**

Galantamine is an alkaloid extracted from Amaryllidaceae and daffodil bulbs, but now synthesized, is a reversible, competitive inhibitor of acetylcholinesterase with very little butyrylcholinesterase inhibitory activity. Galantamine is a cholinsterase inhibitor commonly used in alzheimer's disease. It works by inhibiting acetyl

cholinsterase and improves memory function. Competitive inhibitors compete with acetylcholine at the acetylcholinesterase binding sites, while non- competitive inhibitors bind to the sites independent of acetylcholine concentration. Because competitive acetylcholinesterase inhibitors are dependent on acetylcholine concentration, they may be less likely to bind to the enzymatic site in areas that have high acetylcholine levels [11-12].

### 6. Taxifolin

Taxifolin is a naturally strong antioxidant and anti-inflammatory properties. It hellfire in reducing oxidative stress, protecting neurons from damage and support Blood Brain Barrier repair. Age-related or late-life dementia is characterized by neurodegeneration induced by the accumulation of amyloid plaques and neurofibrillary tangles, and by several overlapping features, including vascular risk factors (e.g., hypertension, diabetes mellitus, and obesity), cerebrovascular diseases, inflammation, and apolipoprotein E (APOE) genotypes. Only a small percentage of people beyond 80 years indeed have “pure Alzheimer’s disease (AD)” or “pure vascular dementia" [13].

## References

[1] Chen L, Guan Y, Wang S, Han X, Guo F, Wang Y. Engineered nanoplatforms for brain-targeted co-delivery of phytochemicals in Alzheimer's disease: Rational design, blood-brain barrier penetration, and multi-target therapeutic synergy. Neurotherapeutics. 2025 Oct;22(6):e00722. doi: 10.1016/j.neurot.2025.e00722. Epub 2025 Aug 14. PMID: 40813153; PMCID: PMC12664471.

[2] Cras P; Kawai M; Lowery D; Gonzalez-DeWhitt P; Greenberg B; Perry G (September 1991). "Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein". Proceedings of the National Academy of Sciences of the United States of America. 88 (17): 7552–6. Bibcode:1991PNAS...88.7552C. doi:10.1073/pnas.88.17.7552. PMC 52339. PMID 1652752.

[3] Purves, Dale; Augustine, George J.; Fitzpatrick, David; Hall, William C.; LaManita, Anthony-Samuel; White, Leonard E.; Mooney, Richard D.; Platt,

ISBN 978-816855388-0

Michael L. (2012). Neuroscience (5th ed.). Sunderland, MA: Sinauer Associates. p. 713. ISBN 978-0-87893-695-3.

[4] Dickson DW (1997). "The pathogenesis of senile plaques". J Neuropathol Exp Neurol. 56 (4): 321–339. doi:10.1097/00005072-199704000-00001. PMID 9100663.

[5] Walker LC (2020). "Aβ plaques". Free Neuropathology. 1 (31): 31. doi:10.17879/freeneuropathology-2020-3025. PMC 7745791. PMID 33345256.

[6] Ballard, C; Gauthier, S; Corbett, A; Brayne, C; Aarsland, D; Jones, E (19 March 2011). "Alzheimer's disease". Lancet. 377 (9770): 1019–31. doi:10.1016/S0140-6736(10)61349-9. PMID 21371747. S2CID 20893019

[7]Belder C, Ballard C, Kales HC, Mummery C, Caramelli P, Ciccarelli O, Frederiksen KS, Gomez-Isla T, Ismail Z, Paquet C, Petersen RC, Perneczky R, Robinson L, Sayin O, Frisoni GB. Treatment for Alzheimer's disease. Lancet. 2025 Sep 27;406(10510):1408-1423. doi: 10.1016/S0140-6736(25)01329-7. Epub 2025 Sep 22. PMID: 40997839.

[8] Wu CK, Fuh JL. A 2025 update on treatment strategies for the Alzheimer's disease spectrum. J Chin Med Assoc. 2025 Jul 1;88(7):495-502. doi: 10.1097/JCMA.0000000000001252. Epub 2025 May 30. PMID: 40442885; PMCID: PMC12637128.

[9] He B, Lu C, Zheng G, He X, Wang M, Chen G, Zhang G, Lu A. Combination therapeutics in complex diseases. J Cell Mol Med. 2016 Dec;20(12):2231-2240. doi: 10.1111/jcmm.12930. Epub 2016 Sep 7. PMID: 27605177; PMCID: PMC5134672.

[10] Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, Winkles JA, Woodworth GF, Kim AJ. Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Curr Pharm Des. 2016;22(9):1177-1193. doi: 10.2174/1381612822666151221150733. PMID: 26685681; PMCID: PMC4900538.

[11] Wilcock G, Wilkinson D. Galanthamine hydrobromide: Interim results of a group comparative, placebo- controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer Type. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM editor(s). Alzheimer's Disease: Biology, Diagnosis and Therapeutics. John Wiley, 1997:661- 664.

[12] Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. doi: 10.1002/14651858.CD001747. Update in: Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. doi: 10.1002/14651858.CD001747.pub2. PMID: 12137632.

# Chapter 2

# Impact of Monogenic Disorders and Calcium Metabolism Polymorphisms in Kidney Stone Disease

**Aanu G S[a], Hema Prabha M P[a], Ramya A[b*]**

[a] *B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences , Vels Institutes of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institutes of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

Kidney stone disease is a common urological disorder that affects nearly 10% of the global population. It is a multifactorial condition influenced by both genetic and metabolic factors. Disturbances in calcium metabolism play a major role in stone formation, and these metabolic processes are tightly regulated by various hormonal mechanisms. Genetic factors, particularly monogenic disorders and genetic polymorphisms, also contribute significantly to the development of kidney stones by altering calcium metabolism. Monogenic stone disorders arise due to inherited mutations in genes responsible for mineral metabolism and renal tubular transport in the kidney. Several inherited conditions, including Dent Disease, Cystinuria, and Primary Hyperoxaluria, are associated with recurrent stone formation.

In addition to these rare genetic mutations, genetic polymorphisms also influence susceptibility to kidney stone disease. Genetic

ISBN 978-816855388-0

polymorphism refers to the occurrence of common DNA sequence variation among individuals within a population. Variations in genes involved in calcium regulation, such as the Calcium-Sensing Receptor and the Vitamin D Receptor, play an important role in maintaining calcium homeostasis. Alterations in these genes may affect intestinal calcium absorption, renal calcium reabsorption, and overall calcium balance, thereby increasing the risk of calcium-based kidney stones.

This chapter provides an overview of calcium metabolism, the genetic basis of monogenic stone disorders, and the role of genetic polymorphisms in modulating calcium homeostasis. Understanding the interaction between hormonal regulation, genetic mutations, and polymorphic variations is essential for improving the diagnosis, prevention, and personalized management of hereditary kidney stone diseases.

*Keywords: Monogenic Stone Disorder; Genetic Polymorphism;* Dent Disease; Cystinuria; Primary Hyperoxaluria;

## 1. Introduction

Kidney stone disease is a prevalent disorder of the urinary tract characterized by the formation of crystalline mineral deposits within the renal collecting system as a result of supersaturation of solutes in urine. This condition, referred to as Nephrolithiasis, affects approximately 10% of the global population and its incidence has been increasing over the past few decades [1,2]. Clinically, patients often present with acute flank pain (renal colic), hematuria, and may also develop urinary tract infections or progressive deterioration of renal function in severe cases [3]. In addition, kidney stone disease is marked by a high recurrence rate, with nearly 50% of individuals

experiencing repeated stone episodes within a few years, thereby imposing a substantial burden on both patient quality of life and healthcare systems [4].

Kidney stone disease develops through a multifactorial process involving interactions between environmental influences, metabolic abnormalities, and genetic susceptibility [5]. Stone formation occurs when urinary solutes become supersaturated, leading to crystal nucleation, growth, and aggregation within the urinary tract [6]. Major stone-forming components include calcium, oxalate, phosphate, urate, and cystine, while substances such as citrate and magnesium act as natural inhibitors of crystallization [7]. Among these, calcium-based stones are the most common, underscoring the importance of disturbances in calcium metabolism in the development of nephrolithiasis [8]. Calcium balance in the body is regulated by coordinated renal and hormonal mechanisms involving key regulators such as Parathyroid Hormone and Vitamin D, which control intestinal absorption, bone resorption, and renal excretion of calcium [9].

In addition to metabolic factors, genetic influences play an important role in kidney stone susceptibility [10]. Some cases arise from monogenic disorders caused by mutations in single genes that affect renal tubular transport and mineral metabolism [11].Examples include Dent disease, cystinuria, and primary hyperoxaluria, which lead to abnormal urinary excretion of stone-forming substances and recurrent nephrolithiasis [12]. Advances in genomic technologies have enabled the identification of several genes responsible for these inherited conditions, improving diagnostic accuracy and understanding of their molecular mechanisms [13].

ISBN 978-816855388-0

Apart from rare monogenic mutations, common genetic variations also influence the risk of kidney stone formation. Genetic polymorphisms are naturally occurring DNA sequence variations that can affect gene expression or protein function [14]. Variations in genes involved in calcium metabolism, particularly the Calcium- Sensing Receptor and Vitamin D Receptor, may alter calcium absorption and renal handling, thereby contributing to stone susceptibility [15]. Understanding the combined effects of monogenic mutations and genetic polymorphisms is essential for clarifying the pathogenesis of nephrolithiasis and may support improved diagnosis, risk prediction, and personalized treatment strategies.

### 1.1. Monogenic Stone Disorder

Monogenic stone disorders represent a subgroup of kidney stone diseases that arise due to pathogenic variants in a single gene affecting renal tubular transport and mineral metabolism. These disorders typically follow patterns of Mendelian Inheritance, including autosomal dominant, autosomal recessive, or X-linked inheritance. In contrast to multifactorial nephrolithiasis, monogenic kidney stone disease is characterized by a strong genetic contribution and often presents with early onset, recurrent stone formation, and a positive family history. Genetic defects usually disrupt the renal handling of lithogenic substances such as calcium, phosphate, oxalate, or cystine, resulting in increased urinary excretion and subsequent crystal formation within the urinary tract.

Several well-characterized monogenic disorders are associated with kidney stone formation. Mutations in the genes SLC3A1 and SLC7A9 lead to Cystinuria, a disorder characterized by impaired renal reabsorption of cystine and dibasic amino acids, resulting in

excessive urinary cystine and recurrent cystine stone formation. Additionally, variants in genes involved in renal phosphate transport, including SLC34A1, SLC34A3, and SLC9A3R1, have been implicated in monogenic kidney stone disease through disruption of phosphate handling and mineral homeostasis. These transport defects increase the urinary concentration of crystallizing solutes, thereby promoting kidney stone formation [16].

### 1.2. Genomic Advances in the Diagnosis of Monogenic Nephrolithiasis

Advances in genomic technologies, particularly whole-exome sequencing, have enabled the identification of numerous genes associated with monogenic nephrolithiasis. Recent cohort studies demonstrate that rare pathogenic variants representing strong genetic risk factors are present in a subset of kidney stone patients, emphasizing the importance of integrating genetic testing with clinical and biochemical evaluation. Identification of such variants can facilitate more precise diagnosis, guide targeted therapeutic interventions, and enable genetic counseling for affected families.

Genetic testing is increasingly important for identifying inherited causes of kidney stone disease (KSD). Research indicates that nearly 15% of kidney stone cases seen in specialized clinics are linked to monogenic disorders resulting from mutations in a single gene. However, performing genetic testing for every patient is not feasible due to high costs and limited resources. As a result, careful selection of patients is necessary to ensure the effective use of genetic testing. Certain clinical characteristics—such as early onset of stone formation, presence of stones in both kidneys, nephrocalcinosis, and a family history of kidney stones—may suggest an underlying genetic

ISBN 978-816855388-0

cause. Patients with these features are therefore often prioritized for genetic evaluation. Recognizing these predictive clinical indicators can help clinicians identify individuals who are more likely to benefit from genetic testing, leading to improved diagnosis and more targeted management of hereditary kidney stone disorders [17].

## 2. Genetic Polymorphism

Genetic polymorphism refers to the presence of two or more variations in a DNA sequence within a population, where the least frequent allele occurs at a frequency of at least 1%. These variations arise through several biological processes, including mutations, errors during DNA replication, genetic recombination during meiosis, and exposure to environmental factors such as radiation or chemical agents. Although many polymorphisms are functionally neutral, some can alter important physiological pathways and contribute to differences in disease susceptibility among individuals. In particular, polymorphisms in genes involved in metabolic regulation, ion transport, and hormonal signaling may influence the risk of complex diseases such as kidney stone disease by affecting processes like calcium absorption, renal calcium reabsorption, and mineral metabolism [18] [19] [20].

### 2.1 Casr Gene Polymorphism in Kidney Stones

A case–control study investigated the relationship between polymorphisms in the calcium-sensing receptor (CaSR) gene and susceptibility to calcium-containing kidney stones in the Kunming Han Chinese population. The study included 100 patients with kidney stones and 100 healthy control individuals. Three CaSR gene polymorphisms—rs1042636, rs1801725, and rs1801726—were analyzed using SNaPshot genotyping technology. The findings

revealed that individuals carrying the rs1801725 GT genotype had a significantly higher risk of developing kidney stones compared with the control group. Moreover, these individuals exhibited increased 24-hour urinary calcium excretion, indicating reduced calcium reabsorption in the renal tubules. The elevated urinary calcium levels may contribute to the formation of calcium-based kidney stones [21].

## 2.2 Clinical Implications




Figure 1: Genetic Basis of Kidney Stone Formation: Monogenic Disorders and Genetic Polymorphisms

Genetic variations, particularly single nucleotide polymorphisms (SNPs) in genes regulating calcium and phosphate transport or hormone signaling, can influence both the risk of kidney stone formation and responses to preventive treatments like thiazide diuretics and vitamin D–based therapies. Evidence from genome- wide association and Mendelian randomization studies suggests that genetic markers related to thiazide response are linked to lower stone risk, indicating that genotype may guide therapy [22]. Variants in calcium-sensing genes (e.g., DGKD), phosphate

ISBN 978-816855388-0

transporters (e.g., SLC34A1), and vitamin D metabolism genes (e.g., CYP24A1, VDR) are associated with changes in urinary calcium and phosphate handling, shedding light on the metabolic pathways underlying nephrolithiasis [23]. As genomic testing becomes more accessible, combining SNP data with biochemical profiles (e.g., urine calcium and citrate) and clinical history can support personalized kidney stone management through tailored surveillance and targeted interventions [24].

## References


[1] Pearle, M. S., Goldfarb, D. S., Assimos, D. G., Curhan, G., Denu-Ciocca, C. J., Matlaga, B. R., Monga, M., Penniston, K. L., Preminger, G. M., Turk, T. M., White, J. R., & American Urological Association (2014). Medical management of kidney stones: AUA guideline. *The Journal of urology*, *192*(2), 316–324.

[2] Worcester, E. M., & Coe, F. L. (2010). Clinical practice. Calcium kidney stones. *The New England journal of medicine*, *363*(10), 954–963. https://doi.org/10.1056/NEJMcp1001011

[3] Curhan G. C. (2007). Epidemiology of stone disease. *The Urologic clinics of North America*, *34*(3), 287–293. https://doi.org/10.1016/j.ucl.2007.04.003

[4] Worcester, E. M., & Coe, F. L. (2008). Nephrolithiasis. *Primary care*, *35*(2), 369–vii. https://doi.org/10.1016/j.pop.2008.01.005

[5] Coe, F. L., Worcester, E. M., & Evan, A. P. (2016). Idiopathic hypercalciuria and formation of calcium renal stones. *Nature reviews. Nephrology*, *12*(9), 519–533. https://doi.org/10.1038/nrneph.2016.101

[6] Goldfarb D. S. (2012). A woman with recurrent calcium phosphate kidney stones. *Clinical journal of the American Society of Nephrology : CJASN*, *7*(7), 1172–1178. https://doi.org/10.2215/CJN.00560112

[7] Holmes, R. P., Knight, J., & Assimos, D. G. (2016). Lowering urinary oxalate excretion to decrease calcium oxalate stone disease. *Urolithiasis*, *44*(1), 27–32. https://doi.org/10.1007/s00240-015-0839-4

[8] Coe, F. L., Evan, A., & Worcester, E. (2005). Kidney stone disease. *The*

*Journal of clinical investigation*, *115*(10), 2598–2608. https://doi.org/10.1172/JCI26662

[9] Bilezikian J. P. (2018). Primary Hyperparathyroidism. *The Journal of clinical endocrinology and metabolism*, *103*(11), 3993–4004. https://doi.org/10.1210/jc.2018-01225

[10] Downie, Mallory & Garcia, Sergio & Kleta, Robert & Bockenhauer, Detlef. (2020). Inherited Tubulopathies of the Kidney: Insights from Genetics. Clinical Journal of the American Society of Nephrology. 16. CJN.14481119. 10.2215/CJN.14481119.

[11] Schueler, M., Halbritter, J., Phelps, I. G., Braun, D. A., Otto, E. A., Porath, J. D., Gee, H. Y., Shendure, J., O'Roak, B. J., Lawson, J. A., Nabhan, M. M., Soliman, N. A., Doherty, D., & Hildebrandt, F. (2016). Large-scale targeted sequencing comparison highlights extreme genetic heterogeneity in nephronophthisis-related ciliopathies. *Journal of medical genetics*, *53*(3), 208–214. https://doi.org/10.1136/jmedgenet-2015-103304

[12] Stechman, M. J., Loh, N. Y., & Thakker, R. V. (2009). Genetic causes of hypercalciuric nephrolithiasis. *Pediatric nephrology (Berlin, Germany)*, *24*(12), 2321–2332. https://doi.org/10.1007/s00467-008-0807-0

[13] Groopman, E. E., Rasouly, H. M., & Gharavi, A. G. (2018). Genomic medicine for kidney disease. *Nature reviews. Nephrology*, *14*(2), 83–104. https://doi.org/10.1038/nrneph.2017.167

[14] Hirschhorn, J. N., & Daly, M. J. (2005). Genome-wide association studies for common diseases and complex traits. *Nature reviews. Genetics*, *6*(2), 95–108. https://doi.org/10.1038/nrg1521

[15] Devuyst, O., & Pirson, Y. (2007). Genetics of hypercalciuric stone forming diseases. *Kidney international*, *72*(9), 1065–1072. https://doi.org/10.1038/sj.ki.5002441

[16] Münch, J., Petrovska, J., Figueiro-Silva, J., Rubio-Aliaga, I., Cabello, E. M., Ivanovski, I., Papik, M., Oneda, B., Fuster, D. G., Seeger, H., Ernandez, T., Buchkremer, F., Wuerzner, G., Dhayat, N. A., Ritter, A., Segerer, S., Roth, B., Rauch, A., Ferraro, P. M., Bonny, O., … Bachmann-Gagescu, R. (2026). Deep biochemical phenotyping reveals prognostic value of rare genetic variants in adult kidney stone disease. *The Journal of clinical investigation*, *136*(5), e196277. https://doi.org/10.1172/JCI196277

[17] Maffei Faccioli, F., Cozzolino, M. G., & Moochhala, S. H. (2026).

ISBN 978-816855388-0

Prioritising genetic testing for kidney stone disease in adults using a clinical scoring system. Clinical kidney journal, 19(2), sfag008. https://doi.org/10.1093/ckj/sfag008

[18] Brookes A. J. (1999). The essence of SNPs. *Gene*, *234*(2), 177–186. https://doi.org/10.1016/s0378-1119(99)00219-x

[19] Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., Gocayne, J. D., Amanatides, P., Ballew, R. M., Huson, D. H., Wortman, J. R., Zhang, Q., Kodira, C. D., Zheng, X. H., Chen, L., Skupski, M., ... Zhu, X. (2001). The sequence of the human genome. *Science (New York, N.Y.)*, *291*(5507), 1304–1351. https://doi.org/10.1126/science.1058040

[20] Sachidanandam, R., Weissman, D., Schmidt, S. C., Kakol, J. M., Stein, L. D., Marth, G., Sherry, S., Mullikin, J. C., Mortimore, B. J., Willey, D. L., Hunt, S. E., Cole, C. G., Coggill, P. C., Rice, C. M., Ning, Z., Rogers, J., Bentley, D. R., Kwok, P. Y., Mardis, E. R., Yeh, R. T., ... International SNP Map Working Group (2001). A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. *Nature*, *409*(6822), 928–933. https://doi.org/10.1038/35057149

[21] Hou, J., Liu, P., Wang, S. *et al.* Association between calcium-Sensing receptor gene polymorphisms and urinary calcium stone formation in the Han Chinese population from a High-Altitude region (Kunming) in China. *Urolithiasis* 54, 28 (2026).

[22] Triozzi JL, Hsi RS, Wang G, et al. Mendelian Randomization Analysis of Genetic Proxies of Thiazide Diuretics and the Reduction of Kidney Stone Risk. *JAMA Netw Open.* 2023;6(11):e2343290. doi:10.1001/jamanetworkopen.2023.43290

[23] Li S, Wang X, Liu M. Genetic susceptibility to kidney stone disease: unveiling pathogenesis and potential therapeutic targets. J Clin Invest. 2025 Aug 1;135(15):e195624. doi: 10.1172/JCI195624. PMID: 40759569; PMCID: PMC12321377.

[24] Singh, P., Harris, P.C., Sas, D.J. *et al.* The genetics of kidney stone disease and nephrocalcinosis. *Nat Rev Nephrol* 18, 224–240 (2022). https://doi.org/10.1038/s41581-021-00513-4

# Chapter 3

# Role of Biomarkers in the Early Detection of Renal Injury

**Hema Prabha M P[a], Aanu G S[a], Ramya A[b*]**

[a]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institutes of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institutes of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

Acute kidney injury (AKI) is a major global health problem associated with significant morbidity and mortality. Conventional diagnostic markers such as serum creatinine and urine output often fail to detect kidney injury at early stages. Therefore, the identification of accurate biomarkers for early detection has become an important focus in nephrology research. Among the emerging biomarkers, urinary neutrophil gelatinase-associated lipocalin (uNGAL) and urinary kidney injury molecule-1 (uKIM-1) have shown considerable promise in identifying renal injury at early stages. These biomarkers are rapidly released following renal tubular damage and can be detected in urine within a few hours after injury. Their high sensitivity and specificity allow earlier diagnosis compared with traditional indicators. This chapter discusses the role of novel biomarkers, including NGAL, KIM-1, IL-18, and L-FABP, in the early detection of

ISBN 978-816855388-0

renal injury and highlights their potential clinical applications in improving diagnosis, monitoring, and management of AKI.

*Keywords: Acute kidney injury (AKI); Biomarkers; urinary neutrophil gelatinase-associated lipocalin (uNGAL); urinary kidney injury molecule-1 (uKIM-1).*

## 1. Introduction

Acute Kidney Injury (AKI) is characterised by a decline in renal function that leads to the accumulation of urea and other waste metabolites together with imbalance of fluid and electrolytes. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines characterize acute kidney injury as a rise in serum creatinine levels of ≥0.3 mg/dl (26.5 µmol/litre) within 48 hours, an elevation in serum creatinine levels to ≥1.5 times the baseline within 7 days, or a urine output <0.5 ml/kg/hour for 6 hours. The Prevailing definition and clinical diagnosis of AKI depend on evaluation of serum creatinine and blood urea nitrogen (BUN). However, these parameters rise only after substantial loss of kidney function, often delaying diagnosis and treatment. Serum creatinine may increase only after 48–72 hours of injury, which limits its effectiveness for early detection [1,2]. To overcome these limitations, considerable research has focused on identifying biomarkers capable of detecting renal injury at earlier stages of disease progression [1,10]. Recent advances in molecular biology and proteomics have led to the discovery of several novel biomarkers such as urinary neutrophil gelatinase-associated lipocalin (uNGAL), urinary kidney injury molecule-1 (uKIM-1), cystatin C, interleukin-18 (IL-18), and liver-type fatty acid-binding protein (L-FABP)[5,6,8,12]. These biomarkers are released in response to

renal injury and may appear in blood or urine within hours of damage [1,11].

### 1.1. Pathophysiology of Acute Kidney Injury

The pathophysiology of AKI involves a significant decline in the glomerular filtration rate (GFR) caused by reduced blood flow to the kidneys, inflammation and tubular injury. The core mechanism includes hemodynamic instability, tubular injury, endothelial dysfunction and intrarenal vasoconstriction [1,10]. The major etiological factors of AKI include ischemia-reperfusion injury, nephrotoxicity and urinary tract obstruction [1,11].

### 1.2. Characteristics of Ideal Biomarkers

A Biomarker should possess several important characteristics for it to be an ideal one. The characteristics are listed below

- Higher sensitivity and specificity
- Ability to recognize injury at an early stage
- Non-invasive evaluation
- Rapid and reliable assay methods
- Prognostics and predictive value
- Ability to identify the type of renal injury
- Cost-effectiveness for clinical use

Different combinations of biomarkers are often employed to promote the precision of diagnosis because no single biomarker satisfies all the above conditions.

## 2. Novel Biomarkers in Early Detection of Renal Injury

### 2.1 Neutrophil Gelatinase-Associated Lipocalin

NGAL is one of the most extensively studied biomarkers for AKI. It is a small protein expressed in neutrophils and epithelial cells. Initially

ISBN 978-816855388-0

discovered in human neutrophils, neutrophil gelatinase-associated lipocalin (NGAL), also known as siderocalin or lipocalin-2 is a 25 kDa polypeptide that is resistant to protease enzymes. The kidney, lungs, and colon are some of the human epithelia where it is expressed in trace amounts. In 2005, Mishra et al. demonstrated that NGAL was a reliable early biomarker of subclinical AKI in pediatric patients following cardiopulmonary bypass; its elevation was maintained throughout the course of AKI and anticipated any increase in serum creatinine by one to three days [1]. The degree of kidney damage is correlated with the level of NGAL expression, which may help identify patients who are at a higher risk of rapid deterioration in renal function [13]. Increased cell proliferation, cytogenesis, renal injury, and the advancement of AKI are all consequences of NGAL expression [1,13]. NGAL has demonstrated a strong association with serum creatinine, cystatin C, and estimated GFR [1]. Additionally, urine NGAL is a measure of normoalbuminuric renal illness in type 2 diabetes mellitus and a good predictor of renal injury prior to apparent changes in eGFR [1, 13].

### 2.2 Kidney Injury Molecule-1

Kidney injury molecule-1 (KIM-1) is a 38.7 kDa type I transmembrane glycoprotein that contains an extracellular immunoglobulin-like domain [8]. Additionally, KIM-1 functions as a phosphatidylserine receptor and converts epithelial cells into semi-professional phagocytes [15]. It is expressed at low levels in the kidney and other organs, but is markedly elevated in kidney injury, particularly following ischemia-reperfusion injury, in some renal tubulointerstitial disorders, and in polycystic kidney disease[8, 15]. Patients with acute tubular necrosis soon after injury had a soluble form of human KIM-1 in their urine, which was linked to the extent

of the lesion, suggesting that KIM-1 could serve as a biomarker for renal proximal tubule damage and related healing processes[7]. KIM-1 is a sensitive biomarker for chronic proximal tubular injury in patients with acute kidney injury (AKI), which is linked to the incidence, progression, and prognosis of the illness. Chronic KIM-1 expression in renal tubules encourages the production of monocyte chemotactic protein 1, which, in turn, promotes fibrosis and a proinflammatory microenvironment [15]. Its expression increases as the illness progresses and is associated with proteinuria and podocytopenia [8].

### 2.3 *Interleukin-18 (IL-18)*

The cytokine interleukin-18 (IL-18) belongs to the IL-1 superfamily [6]. It is produced by several cell types, including monocytes, macrophages, proximal tubular cells, and epithelial cells [6]. IL-18 is synthesized as a 23-kDa inactive precursor, which is cleaved by caspase-1 to form the biologically active 18.3-kDa cytokine [6]. The amount of IL-18 released into the urine following its induction in proximal tubular cells and cleavage by caspase-1 can be measured using an enzyme-linked immunosorbent assay (ELISA) [6]. According to Melnikov et al., kidney IL-18 increases in the context of ischemic acute kidney injury (AKI) and causes tubular necrosis by promoting ischemia-reperfusion injury and neutrophil and monocyte infiltration of the renal parenchyma in early animal models [6]. IL-18's predictive accuracy for AKI has been investigated in a number of clinical contexts, such as after cardiac surgery, in critical patient care, following cardiac catheterisation, and following organ donation [1,6]. According to this research, urine IL-18 levels can be easily and inexpensively quantified and rise early in ischaemic kidney injury

ISBN 978-816855388-0

(about 12 hours before clinical AKI). Its ability to predict AKI is enhanced when IL-18 is combined with other biomarkers [1].

### 3. Liver Fatty Acid-Binding Protein (L-Fabp)

Liver fatty acid–binding protein (L-FABP), also known as FABP1**,** is a 14 kDa soluble protein predominantly found in the cytoplasm of hepatocytes, enterocytes, renal proximal tubular cells, and alveolar epithelial cells [4,12]**.** Under physiological conditions, albumin is primarily reabsorbed in the proximal tubules attached to free fatty acids after being filtered from the glomeruli [14].

Table 1. Major Biomarkers Used in the Early Detection of Renal Injury

| Biomarker | Source | Type of Sample | Time of Elevation After Injury | Clinical Significance | Limitations |
|---|---|---|---|---|---|
| NGAL | Renal tubular epithelial cells | Blood, Urine | 2–4 hours | Early detection of AKI, cardiac surgery AKI | Elevated in infections |
| KIM-1 | Proximal tubular cells | Urine | 6–12 hours | Specific marker of tubular injury | Limited routine availability |
| IL-18 | Proximal tubules, immune cells | Urine | 4–6 hours | Ischemic and inflammatory AKI | Less specific in systemic inflammation |
| L-FABP | Renal tubular cells | Urine | 1–2 hours | Marker of oxidative stress and tubular ischemia | Limited clinical validation |

Following reabsorption, cytosolic albumin enters lysosomes and releases fatty acids to L-FABP [4]. Long-chain fatty acids are bound by L-FABP, which contributes to intracellular signalling, fatty acid

metabolism, and the excretion of lipid peroxidation products, all of which lead to renal protection [4,16]. Urinary L-FABP levels can be measured using a solid-phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle with a functional time of 3.5 hours[14]. Elevated urinary L-FABP levels indicate underlying ischemic tubular stress and have been reported to possess moderate prognostic value for predicting the onset of acute kidney injury (AKI) [12]. Combining biomarkers such as KIM-1 and L-FABP improves diagnostic accuracy and early detection of AKI compared with the use of a single biomarker [3].

## 4. Clinical application of biomarkers for AKI

The identification of AKI biomarkers has evolved, but their application in clinical practice is still relatively new. Acute kidney injury often has multifactorial causes, but the lack of insight into the principal etiology of the acute kidney injury will no doubt hinder studies directed at prevention or treatment of acute kidney injury given the lack of specificity [1, 10]. To date no single biomarker has been shown to be consistently better across a variety of clinical settings. Alternatively, using a panel of biomarkers that are raised under various situations may yield more diagnostic information [3]. The presence of a predictive biomarker or biomarker panel, suggestive of an underlying cause of acute kidney injury, would allow early identification of acute kidney injury and targeting management to the underlying cause, aimed at preventing acute kidney injury. Therefore, continued research and large-scale clinical validation studies are essential to establish reliable biomarker panels for the early diagnosis, prognosis, and effective clinical management of renal injury [1, 10]. The major biomarkers used for the early detection of acute

ISBN 978-816855388-0

kidney injury, along with their sources, sample types, clinical significance, and limitations, are summarized in Table 1.

## 5. Conclusion

Acute kidney injury (AKI) remains a major clinical concern and is associated with significant morbidity, mortality, and healthcare burden worldwide [1,2]. Conventional diagnostic markers such as serum creatinine and blood urea nitrogen are widely used in clinical practice; however, these markers often increase only after considerable loss of renal function, limiting their usefulness for early detection of kidney injury [1]. Consequently, there has been increasing interest in the development of novel biomarkers that can identify renal injury at earlier stages and allow timely intervention.

Several biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and liver fatty acid-binding protein (L-FABP), have demonstrated significant potential for the early detection and prognosis of AKI [6,8,12,13]. These biomarkers reflect different pathological activities involved in renal injury, such as tubular damage, inflammation, oxidative stress, and ischemia [6,8,12]. Because AKI is a complex and multifactorial condition, the use of a single biomarker may not provide sufficient diagnostic accuracy [3].

Despite the promising potential of these biomarkers, several challenges remain before their routine clinical implementation. Variability in study designs, differences in diagnostic cut-off values, and limited validation across diverse patient populations continue to restrict widespread clinical application [1,10]. Thus, further large-scale clinical studies and standardized protocols are necessary to establish reliable biomarker-based diagnostic strategies.

In conclusion, AKI biomarkers represent an important advancement in the early detection and management of renal injury. With continued research, validation, and integration into clinical practice, biomarker-guided approaches may improve early diagnosis, enable targeted therapeutic interventions, and ultimately reduce the progression of kidney injury, the need for renal replacement therapy, and associated mortality [1,2,3].

## References

[1] Mahrukh S Rizvi, Kianoush B Kashani, Biomarkers for Early Detection of Acute Kidney Injury, *The Journal of Applied Laboratory Medicine*, Volume 2, Issue 3, 1 November 2017, Pages 386–399, https://doi.org/10.1373/jalm.2017.023325

[2] Silver, S.A., Long, J., Zheng, Y. and Chertow, G.M. (2017), Cost of Acute Kidney Injury in Hospitalized Patients. Journal of Hospital Medicine, 12: 70-76. https://doi.org/10.12788/jhm.2683

[3] Parikh, C.R., Thiessen-Philbrook, H., Garg, A.X., Kadiyala, D., Shlipak, M.G., Koyner, J.L., Edelstein, C.L., Devarajan, P., Patel, U.D., Zappitelli, M. and Krawczeski, C.D., 2013. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. *Clinical Journal of the American Society of Nephrology*, *8*(7), pp.1079-1088.

[4] Yamamoto, T., Noiri, E., Ono, Y., Doi, K., Negishi, K., Kamijo, A., ... & Sugaya, T. (2007). Renal L-type fatty acid–binding protein in acute ischemic injury. *Journal of the American Society of Nephrology*, *18*(11), 2894-2902.

[5] Herget-Rosenthal, S., Marggraf, G., Hüsing, J., Göring, F., Pietruck, F., Janssen, O., Philipp, T. and Kribben, A., 2004. Early detection of acute renal failure by serum cystatin C. *Kidney international*, *66*(3), pp.1115-1122.

[6] Parikh, C.R., Jani, A., Melnikov, V.Y., Faubel, S. and Edelstein, C.L., 2004. Urinary interleukin-18 is a marker of human acute tubular necrosis. *American Journal of Kidney Diseases*, *43*(3), pp.405-414.

[7] Liangos, O., 2006. Urinary kidney injury molecule-1 level is an early and sensitive marker of acute kidney injury following cardiopulmonary bypass. *J Am Soc Nephrol*, *17*, p.403A.

ISBN 978-816855388-0

[8] Ichimura, T., Hung, C.C., Yang, S.A., Stevens, J.L. and Bonventre, J.V., 2004. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. *American Journal of Physiology-Renal Physiology*, *286*(3), pp.F552-F563.

[9] Kjeldsen, L., Johnsen, A.H., Sengeløv, H. and Borregaard, N., 1993. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *Journal of Biological Chemistry*, *268*(14), pp.10425-10432.

[10] Kramer, A.A., Sutherland, S.M., Hsu, R.K., Kellum, J.A., Bagshaw, S.M., Chawla, L.S., Kane-Gill, S.L., Goldstein, S.L. and Ronco, C., 2016. Utilizing electronic health records to predict acute kidney injury risk and outcomes: Workgroup statements from the 15th ADQI Consensus Conference.

[11] Vaidya, V.S., Ford, G.M., Waikar, S.S., Wang, Y., Clement, M.B., Ramirez, V., Glaab, W.E., Troth, S.P., Sistare, F.D., Prozialeck, W.C. and Edwards, J.R., 2009. A rapid urine test for early detection of kidney injury. *Kidney international*, *76*(1), pp.108-114.

[12] Susantitaphong, P., Siribamrungwong, M., Doi, K., Noiri, E., Terrin, N. and Jaber, B.L., 2013. Performance of urinary liver-type fatty acid–binding protein in acute kidney injury: a meta-analysis. *American Journal of Kidney Diseases*, *61*(3), pp.430-439.

[13] Makris K, Markou N, Evodia E et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med. 2009;47(1):79–82. https://doi.org/10.1515/CCLM.2009.004.

[14] Geng, J., Qiu, Y., Qin, Z. and Su, B., 2021. The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis. *Journal of Translational Medicine*, *19*(1), p.105.

[15] Bonventre, J.V., 2009. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. *Nephrology Dialysis Transplantation*, *24*(11), pp.3265-3268.

[16] Kamijo-Ikemori, A. and Kimura, K., 2015. Urinary liver-type fatty acid binding protein and chronic kidney disease. *Indian Journal of Nephrology*, *25*(5), p.263.

# Chapter 4

# Pharmacological Prevention of Recurrent Stones

**S. Jishnu[a*], Kazi Amin Wasim[a] ,A.Ramya[b*]**

[a]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences , Vels Institutes of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institutes of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

Recurrent nephrolithiasis is a common and challenging condition; with nearly half of affected individuals develop new stones within ten years. Pharmacological prevention, guided by metabolic evaluation and analysis of stone composition, is central to reducing recurrence risk. Thiazide diuretics are widely used in patients with hypercalciuria, as they lower urinary calcium excretion and thereby reduce calcium stone formation. Potassium citrate is effective in correcting hypocitraturia and alkalinizing urine, which prevents calcium oxalate and uric acid stones. Allopurinol, by inhibiting uric acid synthesis, is beneficial in patients with hyperuricosuria or uric acid stones. Other agents, such as magnesium supplements and acetohydroxamic acid, have limited or specialized roles, particularly in struvite stones. Evidence from randomized controlled trials demonstrates that tailored pharmacological therapy, when combined with lifestyle measures such as adequate hydration, sodium restriction, and moderated protein intake, can reduce recurrence

ISBN 978-816855388-0

rates by 40–60%. Despite proven efficacy, long-term adherence and monitoring for adverse effects are essential to ensure sustained benefit. Thus, individualized pharmacological intervention, integrated with dietary and behavioral strategies, represents the cornerstone of recurrent stone prevention and remains a critical component of comprehensive management in patients at risk of recurrence.

*Keywords: Recurrent nephrolithiasis; Kidney stone prevention, Pharmacological therapy; Thiazide diuretics; Hypercalciuria.*

## 1. Introduction

Pharmacological prevention of recurrent stones involves a combination of dietary measures and medications. Thiazide diuretics are commonly used to decrease urinary calcium levels, thereby reducing the recurrence of kidney stones [1,3]. Higher dose of thiazides have been associated with a greater reduction in urinary calcium levels and decreased the kidney recurrent stones [1]. Potassium citrate is another medication that can be used to prevent recurrent stones, especially with recurrent calcium-containing stones. It is recommended for people with recurrent stones with low pH that persists despite nutrition therapy [2,3]. It is essential to consider the patients overall health and the potential side effects of these medications when deciding on the appropriate pharmacological prevention [1].

## 2. Thiazide diuretics

Thiazide diuretics are can be classified into two categories based on their molecular structure: thiazide-type diuretics and thiazide-like diuretics. Examples of thiazide-type diuretics include hydrochlorothiazide, chlorothiazide, and methyclothiazide. Thiazide-

like diuretics such as indapamide, metolazone, and chlorthalidone [7,8]. Possess different molecular structures but share a similar mechanism of action. A meta-analysis of randomized controlled studies in patients with hypertension demonstrated that thiazide-like diuretics provide a 12% greater reduction in cardiovascular events and a 21% greater reduction in heart failure risk compared to thiazide-type diuretics, with comparable adverse event rates [7] .

### 2.1 Mechanism of action

Thiazide diuretics exert their diuretic effect via blockage of the sodium-chloride channel in the proximal segment of the distal convoluted tubule [7,8]. When the channel is blocked. Thiazide diuretics inhibit the sodium–chloride co-transporter in the distal convoluted tubule. This inhibition reduces sodium reabsorption, leading to increased sodium and water excretion in the urine. As a result, urinary calcium excretion is reduced, which contributes to the prevention of calcium stone formation. The activation method for thiazide diuretics can causes the changes in sodium concentration distal to the DCT. This secondary change to balance sodium levels can produce many side effects. The blockage of the sodium channel can cause the increases in sodium and water retention in the lumen and it will decrease the in sodium in the DCT. At the same time blockage of the sodium channel can causes to increase the flow of ions through the sodium channel. This increases the sodium level causes the aldosterone-sensitive sodium or sodium pump to increase the sodium re absorption in the cells of the kidney. This loss the K+ transfer into the collecting as tubules[7]. This loss the k+ pump, which is aldosterone mediated. The results in increased reabsorption of sodium and excretion of both K+ and H+ Ions [8].

ISBN 978-816855388-0

### 2.2 Potassium citrate

The pharmacological prevention of potassium citrate involves the use of potassium citrate to manage the conditions leading to formation of kidney stone [2]. It is used to treat the renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis [2,3]. Potassium citrate works by increasing the urinary citrate level and pH, making the urine less susceptible to the formation of kidney stones. It is particularly effective in preventing calcium phosphate stones and uric acid stones [1,3]. Management of struvite stones should be avoided and they have some infections-related to the kidney [2]. They have some alternative for potassium citrate is sodium bicarbonate or poorly tolerated. The urine sodium will be increases and calcium is essential and the urine can increase the risk of calcium phosphate stones [1]. Studies have shown that potassium citrate therapy may reduce stone recurrence by up to 75% [1].

## 3. Dosage and Administration

The dosage of Potassium citrate can vary based on the condition being treated:

*Adults*: The dosages range from 10 to 30 mEq it will be taken orally and it is divided into two or three doses per day. For better absorption it is administered with meals [7].

*Pediatrics*: For children, the dosage is can be calculated is based on the body weight, typically around 1 to 2 m Eq/kg/day, it will be divides into multiple doses [8].

### 3.1 Allopurinol Therapy

Allopurinol, a xanthine oxidase inhibitor, is a urate-lowering medication [7].

Allopurinol is FDA approved for the following indications:

1. Gout
2. Prevention of tumor lysis syndrome
3. Prevention of recurrent calcium nephrolithiasis in patients with hyperuricosuria [3,7]

Other non-FDA-approved indications include Lesch-Nyhan syndrome-associated hyperuricemia and recurrent uric acid nephrolithiasis prevention [7].

It is important to note that asymptomatic hyperuricemia is not an indication of allopurinol therapy [7] .

### 3.2 Mechanism of action

Allopurinol undergoes metabolism in the liver, where it transforms into its pharmacologically active metabolite, oxypurinol [7]. The half-life of allopurinol is 1 to 2 hours, and oxypurinol is about 15 hours [7]. Both allopurinol and oxypurinol are renally excreted. Allopurinol and oxypurinol both inhibit xanthine oxidase, an enzyme in the purine catabolism pathway that converts hypoxanthine to xanthine to uric acid [7,8].

Prieto-Moure B. et al. conducted research on small intestine ischemia-reperfusion injury of Wistar rats and the role of allopurinol and dantrolene in preventing oxygen-free radical damage. The researchers found that the allopurinol and dantrolene combination provided antioxidant effects, which decreased the oxygen-free radical damage caused by the ischemia-reperfusion in the rat's small intestines.

## 4. *Conclusion*

ISBN 978-816855388-0

Pharmacological therapy remains a cornerstone in the prevention of recurrent nephrolithiasis, particularly in patients with identifiable metabolic abnormalities [1,3]. Thiazide diuretics, potassium citrate, and allopurinol are the most effective and evidence-based agents, each targeting specific risk factors such as hypercalciuria, hypocitraturia, and hyperuricosuria [1,2,3]. While other agents like magnesium supplements and acetohydroxamic acid have limited or specialized applications, their role underscores the importance of individualized treatment. Clinical evidence consistently demonstrates that pharmacological intervention, when combined with lifestyle measures such as adequate hydration, sodium restriction, and moderated protein intake, can reduce recurrence rates by up to 60% [1]. Long-term success depends not only on the appropriate selection of therapy but also on patient adherence and careful monitoring for adverse effects. Ultimately, a tailored, multifaceted approach that integrates pharmacological treatment with dietary and behavioral strategies offers the most effective means of reducing stone recurrence and improving patient outcomes [2,3].

## References

[1] Fink, H. A., Wilt, T. J., Eidman, K. E., Garimella, P. S., MacDonald, R., Rutks, I. R., Brasure, M., Kane, R. L., Ouellette, J., & Monga, M. (2013). Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. *Annals of internal medicine*, *158*(7), 535–543. https://doi.org/10.7326/0003-4819-158-7-201304020-00005

[2] Türk, C., Petřík, A., Sarica, K., Seitz, C., Skolarikos, A., Straub, M., & Knoll, T. (2016). EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. *European urology*, *69*(3), 468–474. https://doi.org/10.1016/j.eururo.2015.07.040.

[3] Pearle, M. S., Goldfarb, D. S., Assimos, D. G., Curhan, G., Denu-Ciocca, C. J., Matlaga, B. R., Monga, M., Penniston, K. L., Preminger,

G. M., Turk, T. M., White, J. R., & American Urological Association (2014). Medical management of kidney stones: AUA guideline. *The Journal of urology*, *192*(2), 316–324. https://doi.org/10.1016/j.juro.2014.05.006.

[4] Pak, C. Y., Peterson, R., Sakhaee, K., Fuller, C., Preminger, G., & Reisch, J. (1985). Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. *The American journal of medicine*, *79*(3), 284–288. https://doi.org/10.1016/0002-9343(85)90305-5.

[5] Maschio G, Tessitore N, D'Angelo A, Fabris A, Pagano F, Tasca A, et al. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol. *Am J Med.* 1981;71(4):623-626.

[6] Brunton LL, Hilal-Dandan R, Knollmann BC. *Goodman & Gilman's The Pharmacological Basis of Therapeutics.* 13th ed. New York: McGraw-Hill; 2018.

ISBN 978-816855388-0

# Chapter 5

# Nanoparticle-Based Drug Delivery Strategies for Crossing the Blood-Brain Barrier in Alzheimer 's disease

**Monika.K[a], Nagammal.B[a], A.Ramya[b*]**

[a]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institutes of Science, Technology & Advanced Studies, Chennai*

[b*]*Assistant Professor, Department of Pharmacology, School of Pharamaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author:ramaya.sps@vistas.ac.in*

**Abstract**

Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by progressive loss of neuronal function, memory impairment, and cognitive decline. Due to the aging population, it is the most prevalent cause of dementia globally and a significant public health concern. Alzheimer's disease is characterized by intracellular neurofibrillary tangles made of hyperphosphorylated tau protein, extracellular amyloid-beta plaque deposition, and persistent neuroinflammation. The brain's gradual neuronal degeneration and disruption of synaptic transmission are caused by these pathological alterations [1][3].The blood–brain barrier (BBB), a highly selective biological barrier that shields the brain from dangerous substances flowing in the bloodstream, is one of the main obstacles to treating Alzheimer's disease. The BBB restricts the delivery of therapeutic medicines to the central nervous system even though it is essential for preserving brain homeostasis. Poor therapy outcomes for

neurological illnesses are caused by many conventional medications' inability to effectively pass the blood-brain barrier [3][4].Recent developments in nanotechnology have presented medication delivery methods based on nanoparticles as viable ways to get around these limitations. Drug stability, bioavailability, and targeted delivery to certain brain regions impacted by neurodegeneration can all be improved by nanoparticles. The potential of a variety of nanocarriers, including lipid nanoparticles, polymeric nanoparticles, dendrimers, and inorganic nanoparticles, to carry therapeutic drugs across the blood-brain barrier via processes such receptor-mediated and adsorptive-mediated transcytosis has been studied [2][5][6].The pathophysiology of Alzheimer's disease, difficulties in delivering medications to the brain, and new advancements in therapeutic approaches based on nanoparticles are all covered in this chapter.

*Keywords:* Alzheimer’s disease, Blood–Brain Barrier (BBB), Nanoparticle-based drug delivery, Brain targeting, Neurodegenerative diseases.

## 1. Introcution

The majority of dementia cases globally are caused by Alzheimer's disease, the most common neurodegenerative illness. Progressive decline in cognitive abilities, such as memory, reasoning capacity, and language proficiency, is a hallmark of the illness. Patients' everyday functioning and quality of life are severely hampered by severe behavioral and psychiatric symptoms as the illness progresses. Alzheimer's disease is becoming more common, which puts a heavy strain on healthcare systems and highlights the need for efficient therapeutic measures [3][5]. Alzheimer's disease is caused by a number of interrelated biological processes. Extracellular

ISBN 978-816855388-0

plaques that obstruct neuronal communication are created when amyloid-beta peptides build up in the brain. Furthermore, aberrant tau protein phosphorylation causes neurofibrillary tangles to form inside neurones, impairing intracellular transport and accelerating neuronal deterioration. Oxidative stress, mitochondrial malfunction, and persistent neuroinflammatory reactions accompany these pathogenic alterations and hasten neuronal destruction [1][3] .

## 2. Blood-brain barrier and drug delivery challenges

The exchange of chemicals between the bloodstream and the central nervous system is controlled by the blood–brain barrier, a sophisticated and highly specialised biological system. Large or hydrophilic molecules cannot passively diffuse into the brain because it is made up of closely spaced endothelial cells that create continuous tight connections. The endothelial cells are surrounded by astrocytes and pericytes, which offer extra structural and functional support to preserve the integrity of the blood-brain barrier [3][4]. The BBB poses a serious obstacle to medication delivery even if it shields the brain from poisons and infections. Many therapeutic treatments are unable to successfully cross the blood-brain barrier, especially big macromolecules and hydrophilic chemicals. Because of this, only a tiny portion of medications are able to reach the brain, which reduces their therapeutic efficacy for treating neurological conditions like Alzheimer's disease [3][7]. The BBB has a number of efflux transporters, such as P-glycoprotein and multidrug resistance proteins, in addition to tight junctions. These transporters actively remove foreign substances from endothelial cells and return them to the bloodstream. Drug buildup in brain tissues is further restricted by these processes. Research in the creation of sophisticated medication delivery methods is now primarily focused on overcoming

these obstacles [4][6]. Drug delivery systems based on nanoparticles have shown promise as a means of circumventing or taking advantage of BBB transport processes. Nanoparticles can interact with cellular transport channels and help deliver therapeutic drugs into the brain because of their small size and adaptable surface characteristics [2][6].

## 3. Nanopartical-based drug delivery systems

By making it possible to create nanoscale carriers that can carry therapeutic drugs to precise target locations, nanotechnology has completely transformed the field of medication delivery. Usually ranging in size from 1 to 100 nanometres, nanoparticles have special physicochemical characteristics that enable them to effectively interact with biological systems. When compared to traditional drug delivery methods, these systems have a number of benefits, including as increased solubility, regulated drug release, and improved drug stability [2][6]. Protecting medications from enzymatic degradation and early removal from the body is one of the main benefits of drug delivery systems based on nanoparticles. When medications are encapsulated in nanoparticles, their bioavailability and circulation time both increase. Moreover, nanoparticles can be designed with surface alterations that enable them to identify and attach to particular BBB receptors, enabling tailored transit into brain regions [1][5]. Dendrimers, inorganic nanocarriers, polymeric nanoparticles, and lipid-based nanoparticles have all been studied as potential treatments for Alzheimer's disease. By delivering therapeutic drugs specifically to damaged brain areas, these nanosystems can increase treatment efficacy while reducing systemic negative effects [5,6]

ISBN 978-816855388-0

## 4. Types of nanoparticles used for brain drug delivery

The potential of several nanoparticle forms to enhance drug transport across the blood-brain barrier in the treatment of Alzheimer's disease has been studied. Due to their great biocompatibility and capacity to incorporate both hydrophilic and hydrophobic medications, lipid-based nanoparticles are the most extensively researched of them. Because their lipid structure is similar to biological membranes, liposomes and solid lipid nanoparticles are very helpful in facilitating drug transport into brain regions and improving their interaction with cellular membranes. Lipid nanoparticles can also enhance the pharmacokinetic characteristics of medicinal compounds and shield them from enzymatic breakdown [5]. Another significant class of nanocarriers for targeted brain medication delivery is polymeric nanoparticles. Biodegradable polymers including chitosan, polyethylene glycol, and polylactic-co-glycolic acid (PLGA) are frequently used to create these nanoparticles. Because polymeric nanoparticles offer sustained and regulated drug release, therapeutic medicines can be active in the body for extended periods of time.

Moreover, ligands or antibodies that selectively attach to blood-brain barrier receptors can be added to their surfaces to improve targeted delivery to impacted brain regions [1][5]. Apart from lipid and polymeric nanoparticles, other nanosystems have also been investigated, including dendrimers, gold nanoparticles, and silica-based nanoparticles. Drug attachment and targeting can be facilitated by the highly branching structure of dendrimers, which have several functional groups. Due to their distinct optical and physicochemical characteristics, metallic nanoparticles—especially gold nanoparticles—are beneficial for both drug administration and diagnostic imaging applications. In neurodegenerative illnesses,

these various nanoparticle systems present intriguing methods for enhancing therapeutic delivery to the brain[5][6] .

## 5. Mechanisms of nanopartical transport across the BBB

Several biological transport pathways allow nanoparticles to get through the blood-brain barrier. Receptor-mediated transcytosis is one of the key processes. This method involves functionalising nanoparticles with ligands that attach to particular receptors on the blood–brain barrier's endothelial cells. These receptors include low-density lipoprotein receptors, insulin receptors, and transferrin receptors. Following its binding to these receptors, the nanoparticle is taken up by the endothelial cell and moved into brain tissues through the blood-brain barrier[6]. Adsorptive-mediated transcytosis is another significant mechanism that happens when negatively charged cell membranes and positively charged nanoparticles interact electrostatically. These interactions let nanoparticles pass through the barrier and are more likely to be absorbed by endothelial cells. This process can improve the penetration of nanoparticles into the brain, but it is less selective than receptor-mediated transport[6]. PEGylation, ligand conjugation, and antibody attachment are examples of surface modification methods that enhance nanoparticles' capacity to pass the blood-brain barrier. These changes improve the stability of nanoparticles, extend their stay in circulation, and improve their capacity to target damaged brain regions. Consequently, nanoparticle transport across the blood-brain barrier has emerged as a key tactic in the creation of sophisticated drug delivery systems for Alzheimer's [1][6] .

ISBN 978-816855388-0

## 6. Recent advances in nanopartical brain delivery

Advanced nanoparticle systems specifically intended for the targeted treatment of neurodegenerative illnesses have been developed as a result of recent nanomedicine research. Researchers have created multipurpose nanoparticles that can transport therapeutic medications straight to the brain's diseased areas. Targeting ligand-containing surface-modified nanoparticles can attach to brain endothelial cell receptors selectively, enabling them to concentrate in Alzheimer's disease-affected brain regions [4][6]. The creation of nanoparticles that can target amyloid-beta plaques, a significant pathogenic aspect of Alzheimer's disease, is another encouraging breakthrough. Drugs can now be administered straight to the sites of pathology thanks to specific nanoparticle formulations that have been designed to identify and attach to these plaques. This focused strategy could halt the development of neurodegeneration and lessen plaque buildup [4][7]. Nanoparticles are being investigated for diagnostic applications in addition to therapeutic delivery. Certain nanoparticles can be employed as imaging agents to identify early pathological alterations in the brain, facilitating an earlier diagnosis and better treatment of the illness. Theranostics, the term for these integrated therapeutic and diagnostic applications, is a new field of study in the management of neurodegenerative diseases [6] .

## 7. Future perspectives

Before nanoparticle-based drug delivery systems can be widely used in clinical practice, a number of issues need to be resolved, despite the fact that they have shown encouraging outcomes in experimental investigations. The long-term safety and possible toxicity of nanoparticles are two of the main issues. Over time, some

nanomaterials may build up in tissues, potentially having negative biological effects. Therefore, prior to clinical application, a thorough assessment of the biocompatibility and toxicity of nanoparticles is required [1][6]. The standardisation and large-scale manufacturing of nanoparticle compositions present another difficulty. Strict quality control procedures and cutting-edge technology are needed to produce nanoparticles with uniform stability, drug loading capacity, and size. Furthermore, the clearance process for innovative treatments may be delayed due to the ongoing evolution of regulatory requirements for nanomedicine products [6]. Future studies should concentrate on creating safer nanomaterials, enhancing targeting effectiveness, and carrying out clinical trials to assess the efficacy of medicines based on nanoparticles in human patients. It is anticipated that developments in biotechnology, materials science, and nanomedicine will aid in the creation of next-generation drug delivery methods that can overcome the present constraints in the treatment of Alzheimer's disease [6][7] .

## 8. Conclusion

Alzheimer's disease is still one of the most difficult neurodegenerative conditions because of its complicated aetiology and few available treatments. The blood-brain barrier, which limits the transport of many therapeutic drugs to brain tissues, is one of the main challenges in creating effective medicines. The therapeutic efficacy of conventional drug delivery methods is typically diminished by their inability to attain sufficient drug concentrations in the brain [1][3]. Drug delivery systems based on nanoparticles offer a potential answer to this problem. Nanoparticles have the potential to greatly enhance Alzheimer's disease treatment outcomes by increasing

ISBN 978-816855388-0

medication stability, boosting bioavailability, and facilitating targeted administration across the blood–brain barrier. Numerous nanocarriers, such as dendrimers, polymeric nanoparticles, and lipid nanoparticles, have shown the capacity to deliver therapeutic medicines into brain regions via a variety of transport modes[5][6]. The design and performance of nanoparticle systems have been further enhanced by recent developments in nanomedicine, allowing for tailored distribution to diseased areas inside the brain. Nanoparticle-based therapeutics are a promising approach for the future treatment of Alzheimer's disease and other neurodegenerative illnesses, but more study is needed to address safety issues and regulatory obstacles [1][3][6].

**References:**

[1] Kochman, U., Sitka, H., Kuźniar, J. et al. Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review. Mol Neurobiol 63, 75 (2026). https://doi.org/10.1007/s12035-025-05417-z

[2] Raghunath, K. (2026). Nanotechnology-based drug delivery systems for brain targeting: Recent advances and challenges. International Journal of Exploring Emerging Trends in Engineering (IJOEETE), 12(1).

[3] Le H, Vu GTT, Abioye A, Adejare A. Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood-Brain Barrier in Targeted Treatment of Alzheimer's Disease. Pharmaceutics. 2026 Feb 1;18(2):192. doi: 10.3390/pharmaceutics18020192. PMID: 41754934; PMCID: PMC12944235.

[4] Haro-Martínez, E., Muscolino, E., Moral, N. et al. Crossing the blood–brain barrier: nanoparticle-based strategies for neurodegenerative disease therapy. Drug Deliv. and Transl. Res. 16, 797–824 (2026).

[5] Rajkumar M, Tian F, Javed B, Prajapati BG, Deepak P, Girigoswami K, Karmegam N. Smart Biosensing Nanomaterials for Alzheimer's Disease: Advances in Design and Drug Delivery Strategies to

Overcome the Blood-Brain Barrier. Biosensors (Basel). 2026 Jan 21;16(1):66. doi: 10.3390/bios16010066. PMID: 41590318; PMCID: PMC12838666.

[6] Lee, S., Lee, J., & Lee, K. (2026). Translational roadmap of BBB-targeted nanoparticle strategies for neuroregenerative therapy in neurodegenerative diseases. Biomaterials Science.

[7] Le H, Vu GTT, Abioye A, Adejare A. Recent Advances in Nanoparticle-Based Drug Delivery Strategies to Cross the Blood-Brain Barrier in Targeted Treatment of Alzheimer's Disease. Pharmaceutics. 2026 Feb 1;18(2):192. doi: 10.3390/pharmaceutics18020192. PMID: 41754934; PMCID: PMC12944235.

[8] Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release 235:34–47

[9] Habib S, Singh M (2022) Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review. Polymers (Basel) 14(4):763.

[10] Teixeira MI, Lopes CM, Amaral MH, Costa PC (2023) Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces 221:112999.

[11] Banks WA (2011) Drug Delivery to the Brain in Alzheimer's Disease: Consideration of the Blood-brain Barrier. Adv Drug Deliv Rev 64(7):629–639.

ISBN 978-816855388-0

# Chapter 6

# The Internal Wildlife of Hypercortisolism: Cushing`S Syndrome

**Kavya.T.U[a], Indira Devi.R[a], Ramya.A[b*]**

[a]*B.Pharmacy 1st year, Vels Institute of Science, Technology & Advanced Studies, Chennai, 600017*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai, 600017*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

Cushing's syndrome can arise from pituitary ACTH, ectopically produced ACTH, an adrenal tumor, or medication. Cushing's disease, which refers to the condition caused by excess pituitary ACTH leading to adrenal gland enlargement, is a complex and challenging endocrine disorder. It should be considered in patients with unusual symptoms for their age, those displaying multiple and worsening features, and those with adrenal incidentalomas. It's also a common issue in children who fail to grow in height percentiles while gaining weight. Endogenous Cushing's syndrome is more prevalent in women. About 80% of cases result from an ACTH-dependent cause, with 80% of those being due to a pituitary adenoma (Cushing's disease) and the remaining 20% due to ectopic ACTH secretion. The other non-ACTH-dependent causes of Cushing's syndrome stem from benign adrenal adenomas (60%) and carcinomas biochemically (40%). Given the specialized nature of the treatment, all cases need to be referred to a major medical center. The most distinctive clinical signs for

diagnosing endogenous Cushing's syndrome include thin skin, easy bruising, and muscle weakness. There should be a strong clinical suspicion before starting investigations. The diagnosis relies on a combination of dexamethasone suppression tests, loss of circadian rhythm, and urine tests for free cortisol. However, differentiating pituitary from non-pituitary sources of excess ACTH should ideally use mical tests. Treatment for endogenous Cushing's syndrome involves using drugs to reduce corticosteroid levels before surgery or in cases where tumors cannot be surgically removed. The preferred surgical approach for Cushing's disease is transsphenoidal surgery; in cases of recurrence or tumors that can't be reset, bilateral laparoscopic adrenalectomy can be considered.

*Keywords: Cushing's syndrome, Exogenous Cushing's syndrome, Endogenous Cushing's syndrome, Excess of glucocorticoids, ACTH.*

## 1. Introduction

### 1.1 Definition

Cushing syndrome is a chronic and systemic clinical condition on the prolonged action of an increase in plasma cortisol levels, ranging from 2 to 8 million people annually. It is not due to a physiological etiology, but due to the most frequent cause of exogenous steroid usage [1]. It is also associated with hyperglycemia, protein catabolism, immunosuppression, hypertension, weight gain, neurocognitive changes, and mood disorders. Cushing's syndrome is an ongoing clinical challenge [1][2].

### 1.2 Historical context

In 1912, Cushing’s syndrome was formally identified by the American neurosurgeon Dr. Harvey Cushing, and it was based on his patient

ISBN 978-816855388-0

Minnie G [2][3]. Initially, it was described as a “polyglandular” disorder involving the pituitary basophilism. Later, it was understood to be the overproduction of ACTH-dependent [pituitary] or independent [adrenal] cortisol, with major advances in diagnosis and treatment emerging throughout the 20th century.[3]

### 1.3 Epidemiology

Cushing`s syndrome is identified as a rare, severe endocrine disorder with an annual disease record of 1.8-4.5 cases per million people. It primarily affects 30-50-year-old adults, with a 3:1 to 4:1 female predominance.[4]




## 2. Etiology and pathophysiology

### 2.1. Exogenous Cushing’s syndrome

Exogenous Cushing syndrome is a form of Cushing`s syndrome that occurs in people taking glucocorticoid (also called corticosteroid, or steroid) hormones. Exogenous Cushing syndrome occurs when a person takes man-made (synthetic) glucocorticoid medicines to treat a disease. These medicines act like cortisol in the body. Prednisone,

dexamethasone, and prednisolone are examples of this type of medicine.

### 2.2. Endogenous Cushing`s syndrome

A rare group of endocrine disorders caused by prolonged and high exposure levels to glucocorticoids of endogenous (adrenal cortex production) origin. Typical clinical features are truncal and facial obesity, hypercatabolic syndrome (thinned skin, purple striae, ecchymosis, bruising with no obvious trauma, proximal muscle weakness with amyotrophy, osteoporosis), and, in children, weight gain with decreasing growth velocity.

### 2.3 Cushing`s disease

Cushing's disease is caused by a tumor or excess growth (hyperplasia) of the pituitary gland. The pituitary gland is located just below the base of the brain. A type of pituitary tumor called an adenoma is the most common cause. An adenoma is a benign tumor (not a cancer).

With Cushing's disease, the pituitary gland releases too much ACTH. ACTH stimulates the production and release of cortisol, a stress hormone. Too much ACTH causes the adrenal glands to make too much cortisol.

## 3. Clinical Manifestations

The syndrome presents with many characteristic physical characteristics, metabolic disturbances, neuro-psychiatric symptoms, and reproductive abnormalities.

### 3.1 *Physical features*

Patients with the syndrome usually exhibit central obesity with thin arms and legs, a round moon face, and a fat hump between the shoulders [buffalo hump]. Pink and purple striae are commonly seen

ISBN 978-816855388-0

on the abdomen, thighs, breasts, and underarms. regions. The skin becomes thin, fragile, and bruises easily, with a slow wound-healing process. Other physical features include acne and hirsutism [excess facial and body hair in women], and temporal balding in females, also in males, who have symptoms like reduced fertility and erectile dysfunction

### 3.2 *Metabolic and cardiovascular effects*

Excess cortisol can lead to hypertension, glucose intolerance, and type 2 diabetes. Patients may also develop osteoporosis, muscle wasting, and weakness, particularly in the proximal muscles of the limbs. Renal calculi and increased susceptibility to infections are additional complications.

### 3.3 *Neuropsychiatric symptoms*

Cushing syndrome can cause depression, anxiety, irritability, and emotional instability. Cognitive effects include trouble concentrating, memory impairment, and Insomnia. Severe cases may present with psychosis or extreme fatigue.

## 4. Diagnostic evaluation and algorithm

Screening tests are essential for identifying underlying, treatable causes in patients such as young - onset hypertension (<30 – 40 years) or secondary osteoporosis.

### 4.1. *Initial screening/ algorithm*

{a} BP measurement

It is done with the help of a 24-hour BP monitor, a device that is used to check your blood pressure automatically throughout the day and night.

{b} Initial labs

Every patient goes through these tests to check their health condition. For kidney functioning, a urine test and a blood test were taken. For the salt level, to check minerals like potassium in your blood, blood sugar, and cholesterol tests were taken for diabetes and heart health, and finally, a thyroid test to check whether the thyroid gland is working properly.

{c} Initial screening

A bone density scan that checks the strength of the bones in the hip and spine, a blood test to check vitamin D and calcium levels in the blood, and hormone issues that might be weakening your bones. A 24-hour urinary free cortisol (UFC) test is conducted to measure the total amount of active cortisol released into urine over 24 hours to diagnose Cushing syndrome and adrenal disorders. I mg overnight dexamethasone suppression test (DST), a common screening tool to determine if the body is producing excess cortisol, a condition known as Cushing's syndrome. If a person takes synthetic steroids like dexamethasone, the pituitary gland stops releasing ACTH hormone, which in turn, the adrenal glands stop making cortisol.

**5. Treatment and management**

Management of Hypercortisolism Syndrome is primarily managed along the lines of Cushing's disease. The goal of management is to reduce plasma cortisol to normal to minimize the potential for complications from hypercortisolism, such as osteoporosis, hypertension, and type 2 diabetes. Endogenous hypercortisolism due to an ACTH-secreting tumor is treated with surgical removal of the tumor. The initial management for Cushing's disease and for an adrenal cortical tumor is surgery. Specifically, the primary

ISBN 978-816855388-0

management of Cushing's disease is with transsphenoidal surgery, and of an adrenal cortical tumor is adrenalectomy.

In the event of surgical failure (because of ectopic ACTH or metastatic adrenal carcinoma) and considering the frequency of drug failure, one can also try to control hypercortisolism medically in the context of Cushing syndrome. In the context of ACTH-dependent disease, adrenalectomy is a possible subsequent option. Pituitary radiation may also be an option in the case of recurrence of Cushing's disease after initial successful surgery.

In 2015, the Endocrine Society released the new guidelines for Cushing syndrome:

Cushing syndrome treatment: The treatment of choice is surgical removal of the adenoma causing the syndrome, excluding situations where steroid levels are not expected to decrease or when surgery is contraindicated. Second-line treatment should be planned on a case-by-case basis.

Alternative first-line treatments include surgical resection of ectopic ACTH-secreting tumors; transsphenoidal selective adenectomy; blocking hormone receptors in cases of bilateral micronodular adrenal hyperplasia; and surgical removal in cases of bilateral adrenal tumors.

### 5.1. *Normalization of cortisol or glucocorticoid activity*

It also includes the normalization of comorbid conditions (such as blood pressure or blood sugar) by additional drugs (such as antihypertensive drugs). Lowering blood glucose or blood pressure in a state of hyperglycemia or hypertension induced by excess cortisol decreases insulin resistance, lipid metabolism abnormalities, and obesity. Although adrenalectomy is a definitive therapy for the great

majority of children and adults suffering from benign unilateral adrenal adenoma, the management of unilateral adrenal carcinomas remains a challenge because of a relatively poor overall prognosis. In this context, surgical removal of the carcinoma is recommended with possible adjunctive therapy with steroid inhibitors to control cortisol hyperproduction.

## 6. Conclusion

Cushing syndrome is a multi-system disease requiring a coordinated approach for prompt diagnosis and treatment to avert high mortality, improve quality of life, and solve problems. Endogenous Cushing's syndrome is a common endocrine disorder caused by chronic glucocorticoid excess. This leads to multiple clinical features, secondary complications, and an increased mortality rate despite treatment. Many of the molecular features and genetic alterations underlying the various causes of Cushing's syndrome have been uncovered over the last decade. The techniques of imaging and biochemical assessment have evolved. The management of Cushing's syndrome is still, however, challenging. Surgery is the first line of treatment for all causes, but medical treatment is becoming increasingly effective with the emergence of new drugs for use in hypercortisolism. Other chronic sequelae and complications, however, remain and can still significantly impact the quality of life of patients who achieve clinical remission. Therefore, accurate and prompt diagnosis and treatment of Cushing's syndrome are important to avert long-term effects of chronic glucocorticoid excess and improve patient survival and well-being. This chapter aims to review and update the management of endogenous Cushing's syndrome of all aetiologies.

ISBN 978-816855388-0

## References

[1] Reincke M, Fleseriu M. Cushing Syndrome: A Review. JAMA. 2023;330(2):170–181. doi:10.1001/jama.2023.11305.

[2] Mônica Gadelha, Federico Gatto, Luiz Eduardo Wildemberg, Maria Fleseriu, Cushing's syndrome, The Lancet, Volume 402, Issue 10418,2023, Pages 2237-2252, ISSN 0140-6736, https://doi.org/10.1016/S0140-6736(23)01961-X.(https://www.sciencedirect.com/science/article/pii/S014067362301961X).

[3] Liu S, Zhou X, Xing J, Huo Z, Zhang M, Yang B, Liu Y, Xia W. Surgical Treatment for Osteomalacia Induced by Causative Tumor in the Knee Joint Region: A Single-Center Retrospective Clinical Study Over 10 Years. Orthop Surg. 2025 Dec;17(12):3440-3455. doi: 10.1111/os.70204. Epub 2025 Nov 18. PMID: 41254933; PMCID: PMC12685467.

[4] Hardy, James D. M.D Surgical Management of Cushing's Syndrome with Emphasis on Adrenal Autotransplantation. Annals of Surgery 188(3): p. 290-307, September 1978.

[5] Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86:117–123.

[6] Biller BM, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibanski A. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab. 1992;75:1303–1309.

[7] Carney JA, Young WF Jr. Primary pigmented nodular adrenocortical disease and its associated conditions. Endocrinologist. 1992;2:6-21.

[8] Kirk JMW, Brain CE, Carson DJ, Hyde JC, Grant DB. Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr. 1999;134:789–792.

[9] Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998;19:647–672.

[10] Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet. 2000;26:89–92.

[11] Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013;369:2105–2114.

[12] Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol. 1992;10:21-27.

[13] Ross EJ, Linch DC. Cushing's syndrome--killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet. 1982;2:646.

[14] Nieman LK. Recent Updates on the Diagnosis and Management of Cushing's Syndrome. Endocrinol Metab (Seoul). 2018;33:139-146.

ISBN 978-816855388-0

# Chapter 7

# Medical Expulsive Therapy in Urolithiasis: Evidence-Based Applications of Alpha Blockers and Calcium Channel Blockers in Calculi

**Krithik,R[a], Albin Binu[a], Ramya.A[b*]**

[a]*Pharm.D-3rd year, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: krithikajith@gmail.com*

**Abstract**

**Background**: Minimally invasive treatments of urolithiasis, including extracorporeal shock wave lithotripsy, ureteroscopy, and percutaneous nephrostolithotomy, have very high efficacy with high cost. The use of medical expulsive therapy (MET) offers a non-surgical and cost-effective alternative to the management of the rightly chosen patient with ureteral calculi.

**Objective**: The purpose of the review is to summarize the modern literature related to MET, as well as providing clinicians with recommendations on the rational use of MET in the treatment of stone disease.

**Methods**: A systematic review of clinical trials, meta-analyses, and AUA/EAU guidelines was conducted to evaluate the effectiveness and safety of medical expulsive therapies suggested, including, calcium channel blockers, corticosteroids, and adrenergic α -adrenoceptor antagonists.

**Results**: AUA/EAU guidelines have confirmed medical expulsive therapy (MET) as a valuable reatment alternative in the management of selected patients. The α-adrenoceptor antagonist and calcium channel blockers have been shown to have a higher success rate in stone-expulsion, with the former proving to be more effective than the latter. Specifically nifedipine and other alpha-antagonists of adrenergic nature have been confirmed as clinically effective, safe and well tolerated. Moreover, it has also been shown that MET also decreases the number of colic bouts, narcotic use, and hospitalization, thus decreasing the number of healthcare expenses and eliminating unnecessary surgical operations.

**Conclusion**: MET is a very effective therapeutic modality in the right selected patient, especially the ones who present with distal ureteral calculi of about 1cm in diameter and is considered to have the option of being managed on observational basis. Even though there is a solid amount of supporting evidence, MET has not been applied clinically to the best of its abilities. The additional contribution of the alpha-adrenergic antagonists and calcium channels blockers include the increased stone clearance rates and analgesic effects in the patients receiving alternative treatments, including shock wave lithotripsy and ureteroscopy.

**Keywords:** Kidney; stones; urolithiasis, alpha blockers , calcium channel blockers.

## 1. Introduction

Urinary stone disease is a prevalent pathological condition that commonly presents with acute severe pain when calculi become lodged in the ureter, frequently necessitating emergency department evaluation.[12] The global prevalence of nephrolithiasis is estimated at

ISBN 978-816855388-0

approximately 10%, with a significant lifetime recurrence rate, placing a substantial burden on healthcare systems worldwide.[1]

The use of medical expulsive therapy (MET), which encompasses alpha-adrenergic antagonists, corticosteroids, and calcium channel blockers, has been extensively reported to facilitate spontaneous passage of ureteral calculi in patients who do not require urgent urologic intervention.[2,3] The American Urological Association (AUA) and the European Association of Urology (EAU) broadly recommend that patients diagnosed with ureteral stones less than 10 mm in diameter who do not require urgent care should receive pharmacologic therapy to facilitate stone passage.[4,5]

An extensive multicenter trial evaluating tamsulosin versus nifedipine in subjects with ureteral stones of any location and size up to 10 mm has contributed important evidence to this clinical debate.[6] Two subsequent meta-analyses have further elucidated the role of MET in ureteral stone management; both identified compelling evidence that tamsulosin and other alpha-blockers are effective and should be prescribed to patients with stones measuring 5–10 mm.[7,8]

Prior research estimated MET utilization rates between 1.1% and 14% among emergency physicians managing urolithiasis patients, suggesting a significant knowledge translation gap that adversely affects patient outcomes and healthcare costs.[10] These studies documenting MET underutilization are limited, however, in their capacity to measure the appropriateness of MET prescribing with respect to alpha-blocker selection.

### 1.1 Objective

Medical expulsive therapy represents an established, pharmacologically based, and cost-effective intervention for ureteral

calculi. Alpha-adrenergic antagonists and calcium channel blockers are the most efficacious pharmacologic agents for facilitating stone passage and constitute the primary treatment recommended by current AUA and EAU guidelines.[3,4] Nevertheless, MET is not uniformly applied across clinical settings, and evidence-based guidance on its correct implementation remains incompletely disseminated.

This review aims to:

- Establish the pharmacological and pathophysiological rationale for MET, including the mechanisms by which alpha-blockers and calcium channel blockers relax ureteral smooth muscle, modulate peristalsis, and reduce intraluminal pressure.
- Systematically evaluate the clinical evidence supporting alpha-adrenergic antagonists — including tamsulosin, silodosin, alfuzosin, terazosin, and doxazosin — as MET agents, with reference to landmark randomized controlled trials (RCTs), Cochrane reviews, and contemporary meta-analyses.
- Evaluate clinical evidence for calcium channel blockers, primarily nifedipine, as an alternative or adjunctive MET strategy, including mechanistic rationale, RCT data, and current limitations.
- Synthesize high-quality evidence and guideline consensus to support clinical decision-making regarding MET pharmacological interventions.

## 2. Methods

To determine the effectiveness and safety of MET in ureteral stones, a systematic review of clinical trials, meta-analyses, and guidelines

ISBN 978-816855388-0

published by the AUA and EAU was performed.[3,4] The review concentrated particularly on calcium channel blockers, corticosteroids, and adrenergic α-adrenoceptor antagonists, their mechanisms of facilitating stone passage, and their safety profiles. Electronic databases searched included PubMed/MEDLINE, Embase, and the Cochrane Library, using the terms: urolithiasis, ureteral calculi, medical expulsive therapy, tamsulosin, alpha-blocker, nifedipine, calcium channel blocker, corticosteroid, stone expulsion, and spontaneous passage.

Inclusion criteria encompassed RCTs, prospective cohort studies, and systematic reviews/meta-analyses published between 2000 and 2024, reporting on stone expulsion rates, time to passage, analgesic requirements, surgical intervention rates, and adverse effects. Studies were assessed for quality using the Cochrane Risk of Bias tool for RCTs and the AMSTAR-2 checklist for meta-analyses.

Treatment of ureteral stones has been transformed by the recognition that most stones — particularly those in the distal ureter measuring less than 10 mm — may pass spontaneously.[9] MET has therefore emerged as a conservative first-line strategy aimed at facilitating stone passage with minimal procedural intervention. The primary mechanism of pharmacologic agents employed in MET is relaxation of ureteral smooth muscle, reduction of spasms, and enhancement of peristaltic coordination, collectively increasing the probability of spontaneous stone expulsion.[13]

## 3. Pharmacology Of Medical Expulsive Therapy

### 3.1 Alpha-Adrenergic Receptor Antagonists

The most extensively studied pharmacologic agents in MET are the α-adrenergic receptor antagonists, owing to their specific effect on

ureteral smooth muscle.[7] α1-Adrenergic receptors — particularly the α1A and α1D subtypes — are highly concentrated in the distal ureter and play a central role in regulating ureteral contractility.[13] Agents including tamsulosin, silodosin, alfuzosin, and doxazosin have been evaluated across numerous RCTs. These drugs reduce ureteral tone and peristaltic frequency while decreasing intraluminal pressure, collectively facilitating stone passage.[14]

Multiple meta-analyses have demonstrated that α-blockers significantly increase stone expulsion rates and shorten time to passage, with the most pronounced benefit observed for distal ureteral stones greater than 5 mm in diameter.[7,8] Tamsulosin (0.4 mg daily) remains the most widely studied and most commonly prescribed agent in this class, demonstrating consistent efficacy across heterogeneous patient populations.[6]

### 3.2 Calcium Channel Blockers

Calcium channel blockers represent a secondary pharmacologic class considered in MET. These drugs attenuate calcium influx into smooth muscle cells by blocking L-type calcium channels, thereby inhibiting ureteral smooth muscle contraction.[15] Nifedipine has been the most extensively studied agent in this category. Although early trials demonstrated promising results, subsequent comparative studies and systematic reviews indicate that calcium channel blockers are modestly less effective than α-adrenergic antagonists and have been progressively de-emphasized in current clinical practice.[5,8]

### 3.3 Corticosteroids

Corticosteroids have been investigated as adjunctive agents in MET based on their anti-inflammatory properties. Ureteral obstruction by a calculus induces mucosal edema and local inflammation that may

ISBN 978-816855388-0

impede spontaneous passage.[16] Short courses of prednisolone, administered in combination with alpha-blockers, have been evaluated for their capacity to reduce ureteral edema and potentially enhance pharmacologic efficacy. While some studies report improved expulsion rates with combination therapy, the adverse-effect profile of systemic corticosteroids does not support their routine use.[16]

## 4. Results

### 4.1 Stone Expulsion Rates and Clinical Outcomes

AUA and EAU guidelines confirm MET as a valuable treatment alternative for appropriately selected patients.[3,4] Both alpha-adrenoceptor blockers and calcium channel blockers have demonstrated superiority over placebo in facilitating stone passage, with alpha-blockers consistently outperforming calcium channel blockers.[7,8] Nifedipine and alpha-adrenergic antagonists have been confirmed as clinically effective, safe, and well tolerated across diverse patient populations.[6]

The effectiveness of MET is significantly influenced by stone size and anatomical location. Pharmacologic therapy produces the most favorable outcomes in distal ureteral stones, with proximal stones substantially less likely to pass spontaneously regardless of treatment.[9] MET demonstrates the greatest benefit for stones measuring 5–10 mm; smaller stones generally pass without pharmacologic assistance.[3]

Meta-analyses pooling data from multiple RCTs have reported stone expulsion rates of approximately 70–87% for alpha-blocker therapy versus 47–65% for placebo, representing a relative risk reduction in surgical intervention of approximately 40–57%.[7,8] Time to stone

expulsion is reduced by a mean of 3–6 days with alpha-blocker therapy compared to controls.[8]

### 4.2 Reduction in Colic, Analgesic Use, and Healthcare Utilization

In addition to improving expulsion rates, MET has been shown to significantly decrease the frequency and severity of renal colic episodes, reduce narcotic analgesic requirements, and decrease rates of hospitalization.[8] These effects collectively contribute to meaningful reductions in healthcare expenditure and avoidance of unnecessary surgical procedures.[2]

### 4.3 Adjunctive Role with Procedural Interventions

Alpha-adrenergic antagonists and calcium channel blockers may provide incremental benefit when used adjunctively in patients undergoing procedural interventions. Evidence suggests that MET administered following ESWL and ureteroscopy facilitates clearance of residual stone fragments, reduces post-procedural pain, and improves overall patient satisfaction.[11]

### 4.4 Safety and Tolerability

The safety profile of pharmacologic MET agents is generally favorable. Alpha-blockers are associated with dizziness, orthostatic hypotension, nasal congestion, and retrograde ejaculation; however, these adverse effects are typically mild and transient.[7] Calcium channel blockers may produce hypotension, headache, and peripheral edema, whereas corticosteroids carry metabolic and immunosuppressive risks when used over extended periods.[16] The favorable tolerability profile of alpha-blockers has solidified their status as the preferred first-line MET pharmacologic class.

ISBN 978-816855388-0

## 5. Conclusion

Medical expulsive therapy represents a highly effective, non-invasive treatment modality for appropriately selected patients with ureteral calculi—specifically those presenting with distal stones of approximately 10 mm or less who are suitable candidates for conservative observational management.[3,9] By relaxing ureteral smooth muscle, reducing spasms, and reducing intraluminal pressure, MET facilitates natural stone passage while maintaining patient comfort and avoiding procedural intervention.[13]

Alpha-adrenergic antagonists—particularly tamsulosin and silodosin—remain the pharmacologic cornerstone of MET, acting through inhibition of α1-adrenergic receptors in the distal ureter to reduce tone, peristaltic frequency, and intraluminal pressure.[7,14] Numerous RCTs and meta-analyses confirm that these agents substantially increase spontaneous expulsion rates, particularly for stones measuring 5–10 mm.[8]

Calcium channel blockers such as nifedipine offer an alternative mechanism via inhibition of L-type calcium channels in ureteral smooth muscle.[15] Early trials yielded promising results; however, the weight of current evidence positions them as second-line agents behind alpha-adrenergic antagonists in contemporary MET protocols.[5]

Despite robust evidence supporting MET, implementation in clinical practice remains suboptimal due to variability in physician awareness, inconsistent practice patterns, and conflicting results from large-scale trials.[10] Current AUA and EAU guidelines continue to support alpha-blocker use in appropriately selected patients with distal ureteral calculi, providing a clear evidence-based framework for

clinical decision-making.[3,4] Beyond standalone conservative management, alpha-blockers and calcium channel blockers provide adjunctive benefits in patients undergoing ESWL or ureteroscopy — facilitating fragment clearance, reducing post-procedural pain, and improving patient-reported outcomes.[11] Additionally, MET reduces analgesic requirements and symptomatic burden during the observation period, enhancing quality of life for patients awaiting spontaneous stone passage.[8]

In conclusion, MET represents a well-evidenced, cost-effective, first-line strategy for distal ureteral calculi amenable to conservative management. Adherence to evidence-based patient selection criteria and guideline-concordant prescribing practices will optimize stone passage outcomes, reduce patient morbidity, and decrease the rates of surgical intervention. Continued investigation into refined patient selection, optimal dosing, and combination regimens will further strengthen MET's role in contemporary urological practice.

## References

[1] Türk C, Neisius A, Petrik A, et al. EAU Guidelines on Urolithiasis. European Association of Urology; 2022.

[2] Preminger GM, Tiselius HG, Assimos DG, et al. 2007 Guideline for the management of ureteral calculi. J Urol. 2007;178(6):2418–2434. doi:10.1016/j.juro.2007.09.107

[3] Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316–324. doi:10.1016/j.juro.2014.05.006

[4] Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: AUA/Endourological Society guideline, part I. J Urol. 2016;196(4):1153–1160. doi:10.1016/j.juro.2016.05.090

ISBN 978-816855388-0

[5] Hollingsworth JM, Canales BK, Rogers MA, et al. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016;355:i6112. doi:10.1136/bmj.i6112

[6] Pickard R, Starr K, MacLennan G, et al. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015;386(9991):341–349. doi:10.1016/S0140-6736(15)60933-3

[7] Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol. 2009;56(3):455–471. doi:10.1016/j.eururo.2009.06.012

[8] Campschroer T, Zhu X, Vernooij RW, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2018;4:CD008509. doi:10.1002/14651858.CD008509.pub3

[9] Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol. 1999;162(3 Pt 1):688–690. doi:10.1097/00005392-199909010-00014

[10] Furyk JS, Chu K, Banks C, et al. Distal ureteric stones and tamsulosin: a double-blind, placebo-controlled, randomized, multicenter trial. Ann Emerg Med. 2016;67(1):86–95. doi:10.1016/j.annemergmed.2015.06.001

[11] Bhatt NR, Davis NF, Flynn R, Thomas AZ, Manecksha RP, Thornhill JA. Dilemmas in the interpretation of evidence for the use of alpha-blockers in ureteric colic: a systematic review. BJU Int. 2019;124(5):740–750. doi:10.1111/bju.14777

[12] Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160–165. doi:10.1016/j.eururo.2012.03.052

[13] Sigala S, Dellabella M, Milanese G, et al. Evidence for the presence of α1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn. 2005;24(2):142–148. doi:10.1002/nau.20108

# Chapter 8

# Influenza Virus: Evolution, Pandemics, and Modern Therapeutic Strategies

**S. Harini[a], A. Ramya[b*]**

[a]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai.*

[b]**Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai.*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

Influenza is a highly contagious viral respiratory disease caused mainly by influenza A and B viruses, which undergo frequent antigenic changes leading to seasonal epidemics and occasional pandemics. It spreads through respiratory droplets and presents with symptoms such as fever, cough, myalgia and respiratory complications, particularly in high-risk groups like children and the elderly. Vaccination remains the most effective prevention measure, while antiviral drugs such as Neuraminidase inhibitors are used for treatment and prophylaxis. However, high mutation rates and antiviral resistance continue to challenge control efforts. Recent advances in Neuraminidase-based vaccine strategies offer promising prospects for broader and longer-lasting protection against diverse influenza strains.

*Keywords: Influenza, Hemagglutinin, Neuraminidase, Oseltamivir, Zanamivir.*

ISBN 978-816855388-0

## 1. Introduction

Influenza is a communicable viral disease that affects the upper respiratory tract, including upper and lower respiratory passages. A wide spectrum of influenza viruses causes it. Some of these viruses can infect humans, and some are specific to different species [1]. It often occurs in outbreaks and epidemics worldwide, mainly during the winter season. Significant numbers of influenza virus particles are present in the respiratory secretions of infected persons, so infection can be transmitted by sneezing and coughing via large particle droplets [2]. Influenza virus infects about 10 million persons worldwide each year. Influenza virus is characterized by a great antigenic variability. Major modifications, called antigenic shifts or type changes, occur approximately three times per century and result in worldwide epidemics--pandemics. Minor modifications, called antigenic drifts or strain changes demand new vaccine compositions each year [3].

### 1.1 Etiology

There are four types of influenza viruses, A, B, C, and D. Influenza types A and B cause human infection annually during the epidemic season. Influenza A has several subtypes according to the combination of hemagglutinin (H) and the neuraminidase (N) proteins that are expressed on the surface of the viruses.

Digitally colorized transmission electron microscopic view of H1N1 influenza virus particles. There are 18 different hemagglutinin subtypes and 11 different neuraminidase subtypes (H1-18 and N1-11). Influenza A viruses can be characterized by the H and N types such as H1N1 and H3N2 (Figure:1. Electron Microscopic View of H1N1 Influenza Virus Particles). Influenza B viruses are

classified into lineages and strains. Influenza B viruses that have circulated in recent influenza seasons belong to one of two lineages, influenza B Yamagata and influenza B Victoria. Influenza viruses have receptors responsible for making them species-specific [4]



Figure 1: Electron Microscopic View of H1N1 Influenza Virus Particles

**1.2 History**

Influenza is a seasonal flu. It is found in the early stage of 412 BC, in the 17th Century it spread wide and got attention from both scientific and lay publications. In the 1889 Russian influenza pandemic, Haemophilus influenza was mistakenly identified as the cause of influenza. Modern science is used to study influenza. In 1933 British physiologist Walter Morley Fletcher isolated influenza as caused by flu. This virus was not identified until the 20th Century [5]. since 1997, avian influenza(H5N1) viruses have caused unprecedented widespread poultry outbreaks with high mortality in number of Asian, European, middle eastern and African countries; have infected other animals; have caused sporadic, severe and fatal human infections [6]. The most severe outbreak known, the 1918 to 1919 influenza A pandemic, was responsible for an estimated 20 million deaths globally. In the United States, the influenza pandemics of

ISBN 978-816855388-0

1957 and 1968 were associated with an attack rate of up to 50% and an estimated 100,000 deaths. Interpandemic influenza is responsible for considerable morbidity and mortality, which exceed that associated with the introduction of the pandemic strain. Influenza B infections resemble those due to influenza A, but are associated with fewer deaths [7].

## 2. Novel strategies for prevention and treatment of influenza

Influenza viruses continue to be a major health challenge due to antigenic variation in envelope proteins and animal reservoirs for the viruses. Vaccination is currently the most effective means of reducing morbidity and mortality during influenza epidemics. In addition, neuraminidase inhibitors have substantially improved antiviral therapy for influenza. However, influenza infection in children and the elderly remain problematic. Furthermore, major innovations in prevention and therapy will be needed to deal with an influenza pandemic. Some adverse sequelae of influenza appear to relate to impairment or pathogenic activation of immune responses. Exciting recent findings in this area, with relevance to influenza treatment, are reviewed [8].

### 2.1 Pandemics

Influenza A pandemics have been responsible for millions of deaths during the past several hundred years. In terms of virulence and lethality, the 1918 to 1919 influenza pandemic was the worst in history. It was unique in its predilection and lethality among young healthy adults. There has never been a satisfactory explanation for the unusual virulence of the 1918 to 1919 pandemic [9]. Influenza pandemics in this century (1946-1947, 1957 and 1968) have fascinated some people for the idea of 11-year pattern pandemic

cycles. In solar physics, it is well known that sunspot cycles also have regular periods of around 11 years. This study therefore aims to investigate the association between sunspot cycles and the occurrences of pandemic influenza. The hypothesis here states that sunspot numbers can detect pandemic influenza A between 1700 and 2000 A.D[10].

### 2.2 Developing Treatment

Treatment of influenza by antiviral drugs can be prophylactic and therapeutic. Amantadine and rimantadine are older drugs effective in cases caused by virus type A. The newest generation of influenza antiviral agents are neuraminidase inhibitors--zanamivir and oseltamivir, effective against both virus types. The symptomatic therapy is still a basis of influenza treatment [11]. Antiviral medications can be used to treat or prevent influenza infection, especially during outbreaks in healthcare settings such as hospitals and residential institutions. Oseltamivir, zanamivir, and peramivir belong to the neuraminidase inhibitors family and can be used for the treatment of influenza A and B. The adamantanes antiviral family has two medications, amantadine, and rimantadine. Amantadine and rimantadine are effective against influenza A, but not influenza B. Oseltamivir can be used for chemoprophylaxis for individuals one year and older in cases of outbreaks and exposure in high-risk groups [12].

### 2.3 Differential Diagnosis

- Acute Respiratory Distress Syndrome
- Adenovirus
- Arenaviruses
- Cytomegalovirus

ISBN 978-816855388-0

- Dengue
- Echovirus infection
- Hantavirus pulmonary syndrome
- Human immunodeficiency virus infections
- Legionnaire disease
- Human parainfluenza virus [13]

**3. Clinical features**

Clinical symptoms such as fever, cough, gastrointestinal symptoms, coma and epilepsy were higher in the severe group. Complications such as pneumorrhagia, heart failure, septic shock, acute renal failure and influenza-associated encephalitis were higher in the severe influenza group than the death group. The laboratory findings including decreased hemoglobin, high alanine aminotransferase, high urea nitrogen and high lactate levels were risk factors for death in children with influenza [14]. Features of influenza include headache, myalgia, malaise, anorexia, sore throat, nonproductive cough, sneezing, and nasal discharge; these symptoms are not pathognomic for influenza, and asymptomatic infection can occur. The pulmonary complications of influenza include pneumonia (viral and bacterial), croup, asthma, and bronchitis. Myocarditis and pericarditis are occasional cardiac complications. Influenza has also been associated with the toxic shock syndrome, myositis, myoglobinuria, and renal failure. In view of its enormous human and economic toll, influenza remains a major target for improved vaccines and vaccine delivery, and antiviral treatment and prophylaxis [15].

**3.1 Influenza vaccine**

The Influenza virus A, B and C causes disease in humans, birds and animals. The Influenza type A causes moderate to severe illness in

all age groups in humans while the illness caused by type B is of milder and it is primarily affecting children. Among many subtypes of influenza A viruses, currently influenza A(H1N1) and A(H3N2) subtypes are circulating among humans. Influenza is a serious public health problem that causes severe illnesses and deaths for higher risk populations. The current human pandemic A/H1N1 is an example of antigenic shift. It slowly established circulation globally; subsequently endemic/seasonal viruses in both hemi-spheres are H3N2 and H1N1. The most effective way to prevent the disease or severe outcomes from the illness is vaccination. The Trivalent Inactivated vaccines (TIV) are of three types: whole virus, split-product, subunit surface-antigen formulations and they are grown in embryonated hen's eggs. Whole-virus vaccines, because of adverse reactions, especially in children, are not currently used. Most influenza vaccines are split-product vaccines, produced from detergent treated, highly purified influenza virus, or surface-antigen vaccines containing purified hemagglutinin and neuraminidase [16].

**4. Antiviral resistance in influenza viruses**

Achieving adequate vaccination rates is challenging and vaccination does not always guarantee complete protection. antiviral drugs represent an important measure to reduce the risk of complications in high-risk patients. influenza viruses have a high mutation rate which causes genetic, biochemical, and pathogenic changes that represent a challenge both for the constant replacement of vaccines and reduce their susceptibility to antiviral action. This makes it necessary to determine the mechanisms of these processes, as well as their epidemiological surveillance and, of course, the development

ISBN 978-816855388-0

of new therapeutic options that may be available in the event of a widespread resistance phenomenon [17].

### 4.1 Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains




The hemagglutinin (HA) surface protein is the primary immune target for most influenza vaccines. The neuraminidase (NA) surface protein is often a secondary target for vaccine designs. computationally optimized broadly reactive antigen (COBRA) methodology was used to generate the N1-I NA vaccine antigen that was designed to cross-react with avian, swine, and human influenza viruses of the N1 NA subtype. The elicited antibodies bound to NA proteins derived from A/California/07/2009 (H1N1) pdm09, A/Brisbane/59/2007 (H1N1), A/Swine/North Carolina/154074/2015 (H1N1), and A/Viet Nam/1203/2004 (H5N1) influenza viruses, with NA-neutralizing activity against a broad panel of HXN1 influenza strains. The

influenza virus NA vaccine antigen allows for protection from multiple HA subtypes and virus host origins, but it has not been the focus of vaccine development. The use of the NA antigen in combination with the HA antigen widens the breadth of protection against various virus strains. Therefore, this research opens the door to the development of a longer-lasting vaccine with increased protective breadth [18].

Figure 2: A/California/07/2009 (H1N1) pdm09 challenge results after vaccination with NA antigens. (A and B) Survival (A) and weight loss (B) curves of mice postinfection are shown. (C) The day 5 peak weight loss of the CA/09-vaccinated mice was significantly different than the mock vaccinated. The variation of the CA/09 NA-vaccinated group was greater than the N1-I-vaccinated group. (D) The viral lung titers determined through plaque assay from lung tissue on day 3 postinfection. All error bars depict standard deviations, and the statistical analysis was conducted using a one-way ANOVA with Tukey's multiple comparison. Not significant (ns); $P$ value < 0.05 (*); $P$ value < 0.01 (**); $P$ value < 0.001 (***); $P$ value < 0.0001 (****) [19].

**5. Influenza surveillance**

Influenza surveillance was established in 1947. From this moment WHO (World Health Organization) has been coordinating international cooperation, with a goal of monitoring influenza virus activity, effective diagnostic of the circulating viruses and informing society about epidemics or pandemics, as well as about emergence of new subtypes of influenza virus type A. As vaccination is the most effective method of fighting the virus, one of the major tasks of GISRS is developing an optimal antigenic composition of the vaccine for the current epidemic season. European Influenza Surveillance Network (EISN) has also developed over the years. EISN is running integrated

ISBN 978-816855388-0

epidemiological and virological influenza surveillance, to provide appropriate data to public health experts in member countries, to enable them undertaking relevant activities based on the current information about influenza activity. In close cooperation with GISRS and EISN are National Influenza Centers--national institutions designated by the Ministry of Health in each Country [19].

## References

[1] Boktor SW, Hafner JW. Influenza. [Updated 2023 Jan 23]. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459363/

[2] Moghadami M. A Narrative Review of Influenza: A Seasonal and Pandemic Disease. Iran J Med Sci. 2017 Jan;42(1):2-13. PMID: 28293045; PMCID: PMC5337761.

[3] Turkulov V, Madle-Samardzija N. Influenca--stalno medu nama [Influenza--always present among us]. Med Pregl. 2000 Mar-Apr;53(3-4):154-8. Croatian. PMID: 10965680.

[4] Jianing He, Yiu-Wing Kam. Insights from Avian influenza: A Review of its multifaceted nature and future pandemic preparedness.2024 mar 17 ;16(3): 458.doi:10.3390/v16030458[PMC Free article] [PUB MED] [Google scholar].

[5] Justin R. Ortiz, Timothy M. Uyeki. avian influenza (H5N1) virus. 25 October2006.https://doi.org/10.1128/9781555815585.ch1 [WILEY online library] [google scholar]

[6] Nicholson KG. Clinical features of influenza. Semin Respir Infect. 1992 Mar;7(1):26-37. PMID: 1609165.

[7] Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am. 2004 Mar;18(1):141-55. doi: 10.1016/S0891-5520(03)00095-3. PMID: 15081510.

[8] Kandel R, Hartshorn KL. Novel strategies for prevention and treatment of influenza. Expert Opin Ther Targets. 2005 Feb;9(1):1-22. doi: 10.1517/14728222.9.1.1. PMID: 15757479.

[9] Yeung JW. A hypothesis: Sunspot cycles may detect pandemic influenza A in 1700-2000 A.D. Med Hypotheses. 2006;67(5):1016-22. doi: 10.1016/j.mehy.2006.03.048. Epub 2006 Jun 27. PMID: 16806734.

[10] Turkulov V, Madle-Samardzija N. Influenca--stalno medu nama [Influenza--always present among us]. Med Pregl. 2000 Mar-Apr;53(3-4):154-8. Croatian. PMID: 10965680.

ISBN 978-816855388-0

# Chapter 9

# The Human Liver: Bridging Biological Function with Pathopharmaceutical Insights

**Sarathi.S [a], Sri Kanthimathy [a], Ramya.A[b*]**

[a]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Science, Vels Institute of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Science, Vels Institute of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

The liver is the largest internal organ in the human body and is considered to be one of the most vital glands in human biology. The liver is involved in metabolism, detoxification, digestion and nutrient storage. This chapter will discuss the basic structure and function of the human liver, which includes its gross anatomy, microscopic anatomy, blood supply, nerve supply, and other vital physiological functions of the human liver. Moreover, some of the common diseases of the liver, which include metabolic dysfunction-associated steatotic liver disease, viral hepatitis, alcohol-associated liver disease, cirrhosis, and hepatocellular carcinoma, are also described in this chapter. The chapter will provide a brief description of the liver and its importance in human biology in a simple way.

*Keywords: Anatomy of liver; Hepatocytes; Metabolism; Bile secretion; Detoxification; Liver disease.*

## 1. Introduction

The liver is the largest visceral organ and the most complex gland in the human body. It plays a vital role in regulating metabolic processes, detoxifying harmful substances, producing bile, and maintaining nutritional balance. Almost all the nutrients that are absorbed from the digestive system pass through the liver via the portal vein. This enables the liver to change and regulate the concentration of these nutrients before they are circulated to the general circulation system [2]. This position enables the liver to act as a protective filter for the body.
The liver also plays a vital role in the body's immune system. Special cells in the liver filter out bacteria, toxins, and worn-out blood cells from the circulation system. The regenerative capacity of the liver also points to its physiological importance. Liver cells have the capacity to regenerate themselves even in the presence of considerable damage to the organ. This regenerative capacity is unique in human organs [1].

## 2. Gross Anatomy of the Human Liver

The liver is situated in the upper right part of the abdominal cavity. It is positioned beneath the diaphragm. The liver is covered by the rib cage. The liver is in close proximity to the stomach, duodenum, pancreas, and the right kidney. The weight of the liver in adults is 1.2-1.5 kg. The liver is soft in texture with a smooth surface and a sharp edge on the inferior surface [1].The liver is divided into *two lobes*: the right and left lobes, based on the presence of the *falciform ligament*. The right lobe is much larger than the left lobe. On the inferior surface, the liver is divided into the *caudate* and *quadrate lobes*. A thin fibrous capsule is present on the external surface of the

ISBN 978-816855388-0

liver. This capsule is known as *Glisson's capsule*. This capsule extends into the liver and supports the vessels and bile ducts [4].

**3. Blood Supply and Nerve Supply of the Liver**

The liver is supplied with blood in a special way to meet the metabolic demands of the body. It receives oxygenated blood through the *hepatic artery* and nutrient-rich blood through the *portal vein*. About 70 to 75% of blood is supplied to the liver through the portal vein. Blood is removed from the liver through the *hepatic veins*, which open into the inferior vena cava [1]. The liver is supplied with *autonomic nerves* that regulate the blood flow, secretion, and metabolism of the liver through the sympathetic and parasympathetic nervous systems.

**3.1 Microscopic Anatomy of the Liver**

In microscopic anatomy, the liver is arranged in a series of plates of liver cells that radiate from a central vein. At the edge of these plates, known as hepatic lobules, there are portal triads that contain a branch of the hepatic artery, portal vein, and bile ducts [1].

The blood moves from the portal triads through the sinusoids to the central vein, where the liver cells are capable of removing the nutrients and detoxifying the harmful substances. At the same time, bile moves out of the liver cells through the bile canaliculi to the bile ducts [4].



### 3.2 Physiological Function of The Liver

Liver has a variety of physiological functions, which are vital for the body. During carbohydrate metabolism, the liver regulates the level of glucose present in the blood by storing the excess glucose in the form of glycogen and using it during the fasting period. It also converts glucose from other sources into the body for continuous supply [2]. This is done through the metabolism of other sources like fats and proteins into glucose. During protein metabolism, the liver is responsible for the synthesis of plasma proteins and the detoxification of ammonia into urea. Lipid metabolism is also carried out by the liver; it converts cholesterol into lipoproteins and bile salts [3].

### 3.3 Bile Secretion and Digestive Function

Bile is a *yellowish-green liquid* that is secreted by *hepatocytes*. Bile plays a vital role in the digestion and absorption of fat. Bile salts have the capability to *emulsify fat* to make it accessible to enzymes. Bile also plays a part in the absorption of *fat-soluble vitamins* and the elimination of waste products such as bilirubin [3].

### 3.4 Detoxification and Storage Functions

Detoxification of drugs, alcohol, and other harmful chemicals, including hormones, takes place in the liver, where the harmful chemicals are converted into water-soluble substances, which are then excreted from the body. The enzymes, such as *cytochrome P450*, play a role in detoxification as well [2]. Storage of vitamins and iron, such as ferritin, occurs in the liver, where vitamins like vitamin B12 are stored for long periods of time. In addition, the liver acts as a blood reservoir during emergency situations [1].

ISBN 978-816855388-0

## 4. Diseases

### 4.1 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

**Etiology and Pathogenesis:** MASLD represents the hepatic manifestation of metabolic syndrome and is caused mainly by insulin resistance, obesity, and type 2 diabetes mellitus [5]. It is defined as the presence of hepatic steatosis of at least 5% and at least one metabolic risk factor, such as hypertension and hyperlipidemia, without the presence of other factors like excessive alcohol use [7]. The disease can range from simple steatohepatitis to Metabolic Dysfunction-Associated Steatohepatitis (MASH), which involves hepatocellular damage and lobular inflammation [7].

**Diagnostics and Management:** The Fibrosis-4 (FIB-4) index is the recommended initial diagnostic tool for assessing the risk of advanced hepatic fibrosis [8]. Although the definitive diagnostic tool for the disease remains liver biopsy, non-invasive tests (NITs) like Vibration-Controlled Transient Elastography (VCTE) have been gaining popularity as a monitoring tool [8]. The management strategy for the disease involves weight loss of 7-10% due to lifestyle modifications, which have been found to improve steatohepatitis [5]. The management also includes Resmetirom, a thyroid hormone receptor-β selective agonist for the treatment of advanced hepatic fibrosis, and GLP-1 receptor agonists like Semaglutide for the management of associated conditions like obesity and diabetes [5].

### 4.2 Chronic Viral Hepatitis (HBV and HCV)

**Etiology and Pathogenesis:** The etiology of chronic hepatitis is due to infection with the Hepatitis B (HBV) and Hepatitis C (HCV) viruses, both of which cause chronic necroinflammatory changes and can

result in cirrhosis [6, 9]. HBV is a DNA virus, and the virus integrates into the genome, whereas HCV is an RNA virus [9]. The cumulative risk for hepatocellular carcinoma (HCC) is high due to immunologic destruction of hepatocytes[9].

**Diagnostics and Management:** Diagnosis is established through serological markers (HBsAg for HBV; anti-HCV for HCV) followed by quantitative PCR to determine viral load [9]. Management of HBV focuses on lifelong suppression of viral replication using nucleos(t)ide analogues like *Tenofovir (TDF/TAF)* or *Entecavir* [7]. For HCV, the standard of care is the use of pan-genotypic Direct-Acting Antivirals (DAAs) like *Sofosbuvir/Velpatasvir*, which can achieve a Sustained Virologic Response (SVR) in over 95% of patients after 8–12 weeks of therapy [6].

**5. Alcohol-Associated Liver Disease (ALD)**

**Etiology and Spectrum:** ALD is caused by excessive and prolonged consumption of ethanol, leading to mitochondrial damage and oxidative stress through its metabolite, acetaldehyde [9]. ALD includes a variety of conditions from alcoholic steatosis, acute hepatitis, and chronic cirrhosis [9]. ALD is increasingly becoming a major risk factor for death from liver disease, especially with malnutrition and sarcopenia in its late stages.

**Diagnostics and Management:** ALD is diagnosed based on a history of excessive ethanol consumption and raised liver enzyme levels, such as an AST/ALT ratio > 2:1 and raised levels of GGT enzyme [9]. Disease severity is often determined based on MELD scores and Maddrey Discriminant Function [10]. Abstinence from alcohol is considered the only cure for ALD, as it is the only intervention that completely stops disease progression [10]. Corticosteroids, such as

ISBN 978-816855388-0

Prednisolone, may be considered for reducing mortality rates among patients suffering from severe acute hepatitis [10].

### 5.1 Cirrhosis and Hepatocellular Carcinoma (HCC)

**Etiology and Malignancy:** Cirrhosis is the end-stage of chronic liver inflammation, where 80–90% of HCC cases arise within a cirrhotic environment [9]. HCC is currently the third leading cause of cancer-related mortality globally [11]. Transformation into malignancy involves complex molecular changes, often in the setting of portal hypertension and regenerative nodules [9, 12].

**Diagnostics and Management:** Surveillance for HCC in cirrhotic patients is recommended every six months using ultrasound and Alpha-fetoprotein (AFP) [12]. Diagnosis is confirmed via multiphasic CT or MRI using *LI-RADS* criteria [11]. Treatment follows the *BCLC staging system:* early-stage tumors are managed with surgical resection, thermal ablation, or liver transplantation [12]. For advanced-stage disease (BCLC C), systemic combination immunotherapies, specifically *Atezolizumab plus Bevacizumab*, have become the first-line standard of care, significantly improving overall survival compared to older tyrosine kinase inhibitors [11, 13].

## 6. Conclusion

The human liver is an essential organ in the human body and plays a vital role as the main hub for metabolism, detoxification, and immune defense. The complex gross and microscopic anatomy of the human liver enables it to filter nutrients and harmful substances before they enter the human body. Moreover, the liver's remarkable regenerative capacity makes it a vital organ for human survival. In addition to its vital roles in the human body, the liver's remarkable regenerative capacity makes it a vital organ for human survival.

However, the human liver is vulnerable to various severe health problems, ranging from metabolic disorders such as MASLD to infections such as viral hepatitis and alcoholic liver diseases. If not properly managed in the early stages, the human liver is vulnerable to severe end-stage cirrhosis and liver cancer. It is vital for the students and future medical practitioners to understand the vital relationship between the human liver and metabolic balance in the human body.

## References

[1] Gray, H. (2021). Gray's Anatomy: The Anatomical Basis of Clinical Practice. Elsevier.https://shop.elsevier.com/books/grays-anatomy/standring/978-0-7020-7705-0

[2] Guyton, A. C., & Hall, J. E. (2020). Guyton and Hall Textbook of Medical Physiology. Elsevier https://shop.elsevier.com/books/guyton-and-hall-textbook-of-medical-physiology/hall/9780323597128

[3] Ganong, W. F. (2018). Review of Medical Physiology. McGraw-Hill Education.https://accessmedicine.mhmedical.com/book.aspx?bookid=2525

[4] Standring, S. (2021). Gray's Anatomy for Students. Elsevier.https://shop.elsevier.com/books/grays-anatomy-for-students/drake/9780323636391

[5] Hepatology Textbook. (2024). Chapter 9 – MASLD / MASH. *11th Edition 2024–2025*. https://www.hepatologytextbook.com/book/chapter_09.php

[6] Korean Association for the Study of the Liver (KASL). (2025). 2025 KASL clinical practice guidelines for management of hepatitis C. *Clinical and Molecular Hepatology*. https://www.e-cmh.org/journal/view.php?number=2363

[7] Elshaer, A., Chascsa, D. M. H., & Lizaola-Mayo, B. C. (2024). Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). *Life*, *14*(7), 844. https://doi.org/10.3390/life14070844

[8] Dawod, S., & Brown, K. (2024). Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. *Frontiers in Medicine*, *11*. https://doi.org/10.3389/fmed.2024.1499013

ISBN 978-816855388-0

[9]Kinsey, E., & Lee, H. M. (2024). Hepatocellular Carcinoma: A Comprehensive Review. *Cancers*, *16*(3), 666. https://doi.org/10.3390/cancers16030666

[10] European Association for the Study of the Liver (EASL). (2024). EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *Journal of Hepatology*. https://easl.eu/wp-content/uploads/2018/10/EASL-CPG-nutrition-in-chronic-liver-disease.pdf

[11] Gordan, J. D., Kennedy, E. B., Abou-Alfa, G. K., et al. (2024). Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. *Journal of Clinical Oncology*, *42*(15), 1830-1850. https://doi.org/10.1200/jco.23.02745

[12] Kinsey, E., & Lee, H. M. (2024). Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape. *Cancers*, *16*(3), 666. https://doi.org/10.3390/cancers16030666

[13] Mayo Clinic. (2025). Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma. *Journal of Hepatology*. https://www.dovepress.com/article/download/111236

[14]https://vectormine.com/item/liver-structure-and-anatomical-organ-function-explanation-outline-diagram/?utm_source=pinterest&utm_medium=social

# Chapter 10

# Fragile X Syndrome: A Comprehensive Review of Etiology, Pathophysiology, and Management

**Shagufta Naz.A[a], Snigdha Bairagi[a], A.Ramya[b*]**

[a] *B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences , Vels Institutes of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institutes of Science, Technology & Advanced Studies, Chennai*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

Fragile X syndrome (FXS) is the most common inherited single-gene cause of intellectual disability and a significant genetic cause of autism spectrum disorder. The disorder shows variable expressivity and reduced penetrance, especially in females due to X-chromosome inactivation. Clinically, FXS is associated with intellectual disability, behavioral problems, anxiety, and autism-related features. Diagnosis is mainly performed using molecular genetic tests such as PCR and Southern blot analysis to detect CGG repeat expansion and methylation status.

*Keywords:* FMR1; Gene therapy, treatment, fragile X messenger ribonucleo protein (FMRP);

## 1. Introduction

Fragile X syndrome (FXS), also known as Martin-Bell syndrome in the past, is a non-Mendelian trinucleotide repeat disorder [1]. Fragile X syndrome (FXS) is the most common single-gene cause of inherited

ISBN 978-816855388-0

intellectual disability. FXS is caused by an expanded trinucleotide repeat (CGG) on the 5′ untranslated region of the fragile x mental retardation 1 (*FMR1*) gene. A normal range is between 6 and 44 repeats. Individuals with 45 to 54 repeats are considered to have a gray zone or intermediate expansion. Those with 55 to 200 repeats have the permutation, which is likely to become unstable in future generations. Affected individuals with the full mutation FXS have >200 repeats [3]. However, the biological mechanism responsible for the presentation of FXS is not fully understood. Approximately 30% of girls and 90% of boys with the full mutation have intellectual disability, and 60% of boys are diagnosed with autism spectrum disorder (ASD). Anxiety disorders occur in 70–80% of individuals with FXS [4]. FXS testing should be a consideration in the differential diagnosis of any individual with intellectual disabilities, impaired development, or autism of unknown etiology. In addition, all individuals older than 50 years with ataxia and tremors or females with premature ovarian insufficiency should be tested for this premutation. Molecular genetic tests, rather than cytogenetics, are now used to diagnose FXS. There is no cure for the disease, but early diagnosis and intervention can improve patients' and families' prognosis and quality of life and aid them in their future reproductive decisions[1]. Unfortunately, clinicians frequently do not diagnose this condition due to several factors, including similar clinical features as other syndromes, various presenting phenotypes, and frequent absence of clinical features at birth. Therefore, FXS is underdiagnosed, leading to suboptimal management and patient outcomes[9].

## 2. Etiology

FXS is an X-linked dominant condition with variable expressivity and reduced penetrance[5]. One reason is the differing number of CGG repeats in the *FMR1* gene in affected individuals. Those without the disorder have 5 to 44 CGG repeats. However, individuals with abnormal alleles are classified according to their expanded number of CGG repetitions[6]. Furthermore, due to X-inactivation in females and genetic anticipation, the inheritance of FXS does not follow standard X-linked dominant inheritance. Females with full FMR1 mutations have a milder phenotypic presentation than males, secondary to the protection provided by an additional unaffected X chromosome [6][7].

## 3. Epidemiology

FXS with a full mutation allele occurs in approximately 1 in 7000 males and 1 in 11,000 females; however, the exact frequency is unknown[10]. However, it is essential to note that the carrier frequency can vary greatly based on the diagnostic testing used and the population of interest, with specific populations showing significantly higher or lower disease prevalence[11-13]. For instance, the prevalence in Columbian males is reported to be 1 in 20, which is 343 times higher than the rest of the world[14].

## 4. Pathophysiology

FXS is indirectly the result of the expansion of the CGG triplet repeat within the fragile X mental retardation 1 gene (*FMR1*) located on the X chromosome, which silences *FMR1* expression[15]. This CGG expansion is due to abolished or greatly diminished fragile X mental retardation protein (FMRP) and is the direct cause of FXS**[16].** Point mutations or deletions may also be a cause of reduced functional

ISBN 978-816855388-0

FMRP[17]. FMRP is a master regulator that directs protein translation, impacting neuronal connections, synaptic plasticity, and ovarian functions[18].

## 5. Treatment

### 5.1 Supportive therapies

There is no cure for FXS; therefore, management primarily involves symptomatic treatment, including speech therapy, behavioral therapy, sensory integration, occupational therapy, and special education[15][22]. Furthermore, providing occupational therapy and tailored training for individuals affected by the condition can help them achieve greater independence, improve their self-care skills, and receive vocational training[14].

### 5.2 Pharmacologic therapies

Medications used for symptom-based treatment aim to minimize some behavioral and mental health challenges associated with FXS. Stimulants may target hyperactivity, impulsivity, and attention issues. Antidepressants (eg, bupropion, buspirone, or selective serotonin and norepinephrine reuptake inhibitors) may treat anxiety, obsessive-compulsive behaviors, and mood disorders. Drugs targeting the metabotropic glutamate receptors linked with synaptic plasticity have been demonstrated to be particularly beneficial[14]. Adverse effects specific to the FXS population may occur with most of the abovementioned agents. Therefore, medication management is best done by the practitioner's familiarity with the drug and the FXS population[14].

## 6. Differential diagnosis

Differential diagnoses to be considered in cases of suspected FXS include [1]:

- Sotos syndrome
- Prader-Willi syndrome
- Klinefelter syndrome
- Rett syndrome
- Trisomy 21
- Metabolic disorder
- Autism

## 7. Search Terms and Inclusion/Exclusion Criteria by Topic Area

| Topic Area | Search Terms | Search Dates | Other Search Criteria |
|---|---|---|---|
| Full mutation phenotype | Fragile X syndrome, fragile X–associated disorders, fragile X premutation, fragile X carrier, fragile X–associated tremor/ataxia syndrome, or fragile X–associated primary ovarian insufficiency and phenotype, clinical presentation, description, neurocognitive, cognitive, behaviour, social-emotional, or language, communication | 2008–2014 | English language Human United States only |
| Developmental trajectories across the life span | Fragile X syndrome or fragile X and lifespan, developmental, longitudinal, adolescent, adult, services, or transition to adulthood | 1991–2014 | English language Human |

ISBN 978-816855388-0

| Topic Area | Search Terms | Search Dates | Other Search Criteria |
|---|---|---|---|
| Available interventions and treatments | Fragile X syndrome or fragile X and treatment, intervention, pharmacological, educational, behavioral, medication, or clinical trial | 1991–2014 | English language Human |
| Impact on family | Fragile X syndrome or fragile X and family adaptation, family impact, family outcomes, burden, or cost of care | 1991–2014 | English language Human United States only |

## 8. Conclusion

Despite the progress in many areas of FXS research, work remains to address gaps in clinical and public health knowledge. We pose 3 main areas of focused research, including early detection and diagnosis, determinants of health, and development and implementation of targeted

## References

[1] Shah M, Los E. Fragile X Syndrome. [Updated 2023 Oct 28]. In: StatPeSarls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from

[2] Raspa M, Wheeler A, Okoniewski KC, Edwards A, Scott S. Research Gaps in Fragile X Syndrome: An Updated Literature Review to Inform Clinical and Public Health Practice. J Dev Behav Pediatr. 2023 Jan 1;44(1):e56-e65. 10.1097/DBP.0000000000001134. Epub 2022 Oct 11. PMID: 36219479; PMCID: PMC977015

[3] Raspa M, Wheeler AC, Riley C. Public Health Literature Review of Fragile X Syndrome. Pediatrics. 2017 Jun;139(Suppl 3):S153-S171. Doi: 10.1542/peds.2016-1159C. PMID: 28814537; PMCID: PMC5621610.

[4] https://www.gacetamedicademexico.com/frame_esp.php?id=385#

[5] Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012 Dec;122(12):4314-22.

[6] Liang Q, Liu Y, Liu Y, Duan R, Meng W, Zhan J, Xia J, Mao A, Liang D, Wu L. Comprehensive Analysis of Fragile X Syndrome: Full Characterization of the FMR1 Locus by Long-Read Sequencing. Clin Chem. 2022 Dec 06;68(12):1529-1540.

[7] Mila M, Alvarez-Mora MI, Madrigal I, Rodriguez-Revenga L. Fragile X syndrome: An overview and update of the FMR1 gene. Clin Genet. 2018 Feb;93(2):197-205.

[8] Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012 Dec;122(12):4314-22.

[9] Movaghar A, Page D, Brilliant M, Mailick M. Prevalence of Underdiagnosed Fragile X Syndrome in 2 Health Systems. JAMA Netw Open. 2021 Dec 01;4(12):e2141516.

[10] Razak KA, Dominick KC, Erickson CA. Developmental studies in fragile X syndrome. J Neurodev Disord. 2020 May 02;12(1):13.

[11] Winarni TI, Utari A, Mundhofir FE, Tong T, Durbin-Johnson B, Farads' SM, Tassone F. Identification of expanded alleles of the FMR1 gene among high-risk population in Indonesia by using blood spot screening. Genet Test Mol Biomarkers. 2012 Mar;16(3):162-6.

[12] Saldarriaga W, Forero-Forero JV, González-Teshima LY, Fandiño-Losada A, Isaza C, Tovar-Cuevas JR, Silva M, Choudhary NS, Tang HT, Aguilar-Gaxiola S, Hagerman RJ, Tassone F. Genetic cluster of fragile X syndrome in a Colombian district. J Hum Genet. 2018 Apr;63(4):509-516.

[13] Otsuka S, Sakamoto Y, Siomi H, Itakura M, Yamamoto K, Matumoto H, Sasaki T, Kato N, Nanba E. Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain Dev. 2010 Feb;32(2):1.

[14] Acero-Garcés DO, Saldarriaga W, Cabal-Herrera AM, Rojas CA, Hagerman RJ. Fragile X Syndrome in children. Colomb Med (Cali). 2023 Apr-Jun;54(2):e4005089.

[15] Macpherson JN, Murray A. Development of Genetic Testing for Fragile X Syndrome and Associated Disorders, and Estimates of the

ISBN 978-816855388-0

Prevalence of FMR1 Expansion Mutations. Genes (Basel). 2016 Nov 30;7(12)

[16] Macpherson JN, Murray A. Development of Genetic Testing for Fragile X Syndrome and Associated Disorders, and Estimates of the Prevalence of FMR1 Expansion Mutations. Genes (Basel). 2016 Nov 30;7(12)

[17] Salcedo-Arellano MJ, Dufour B, McLennan Y, Martinez-Cerdeno V, Hagerman R. Fragile X syndrome and associated disorders: Clinical aspects and pathology. Neuropil Dis. 2020 Mar;136:104740.

[18] Hagerman PJ, Hagerman R. Fragile X syndrome. Curr Biol. 2021 Mar 22;31(6):R273-R275.

[19] Zangenehpour S, Cornish KM, Chaudhuri A. Whole-brain expression analysis of FMRP in adult monkey and its relationship to cognitive deficits in fragile X syndrome. Brain Res. 2009 Apr 06;1264:76-84.

[20] Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL, Hagerman PJ. Fragile X syndrome. Nat Rev Dis Primers. 2017 Sep 29;3:17065.

[21] Raspa M, Wheeler A, Okoniewski KC, Edwards A, Scott S. Research Gaps in Fragile X Syndrome: An Updated Literature Review to Inform Clinical and Public Health Practice. J Dev Behav Pediatr. 2023 Jan 01;44(1):e56-e65.

[22] Hersh JH, Saul RA., Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics. 2011 May;127(5):994-1006.

# Chapter 11

# Nano Robots for Targeted Drug Delivery

**Snigdha Bairagi[a*], Shagufta Naz[b], A.Ramya[b]**

[a*]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai.*

[b]*B.Pharm Student, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, technology & Advanced Studies, Chennai.*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai.*

** Corresponding Author: ramya.sps@vistas.ac.in*

**Abstract**

Nanotechnology has emerged as a revolutionary field in modern medicine, particularly in drug delivery systems. Nanorobots are nanoscale devices designed to perform specific tasks within the human body, including targeted drug delivery to diseased tissues. These microscopic machines can navigate through the bloodstream, recognize specific biological signals, and release therapeutic agents directly at the disease site. Targeted drug delivery using nanorobots improves treatment efficiency while minimizing systemic side effects. The integration of nanotechnology, biotechnology, and artificial intelligence has significantly advanced the development of nanorobotic systems. Nanorobots have shown promising applications in cancer therapy, cardiovascular diseases, and neurological disorders. This chapter discusses the concept, epidemiology,

ISBN 978-816855388-0

pathophysiology, clinical relevance, and emerging research related to nanorobots for targeted drug delivery.

*Keywords:* Nanorobots, Targeted drug delivery, Nanotechnology, Nanomedicine, Drug delivery systems, Cancer therapy.

## 1. Introduction

Nanotechnology plays an important role in improving modern pharmaceutical drug delivery systems. It involves the manipulation of materials at the nanoscale level, typically ranging from 1 to 100 nanometers. Nanorobots are tiny robotic devices designed using nanotechnology that can perform specific medical tasks within the human body [1].

Traditional drug delivery systems often distribute drugs throughout the body, which can lead to unwanted side effects and reduced therapeutic efficiency. Targeted drug delivery aims to deliver drugs specifically to diseased tissues while minimizing damage to healthy cells [2].

Nanorobots are engineered to travel through blood vessels, identify diseased cells, and release drugs directly at the target site. These devices may be controlled by external magnetic fields, chemical signals, or biological interactions. The use of nanorobots in drug delivery can significantly improve drug bioavailability, reduce toxicity, and enhance therapeutic outcomes [3].

Recent advances in biomedical engineering, artificial intelligence, and nanotechnology have accelerated the development of nanorobots for medical applications. Although many nanorobotic systems are still in the experimental stage, they hold great potential for future clinical use [4].

## 2. Epidemiology

Many life-threatening diseases such as cancer, cardiovascular diseases, and neurological disorders require highly precise drug delivery systems. Cancer alone is one of the leading causes of death worldwide, accounting for millions of deaths each year [5].

Conventional treatments like chemotherapy often affect both healthy and diseased cells, leading to severe side effects. Targeted drug delivery using nanorobots has the potential to improve treatment outcomes by delivering drugs directly to tumour tissues while minimizing damage to normal cells [6].

The growing prevalence of chronic diseases has increased the need for advanced drug delivery technologies. Nanorobotic systems are considered promising tools for improving therapeutic efficiency and reducing drug-related toxicity [7].

## 3. Pathophysiology

The effectiveness of drug therapy depends largely on the ability of drugs to reach the target tissue at an adequate concentration. In many diseases, physiological barriers such as cell membranes, blood-brain barrier, and enzymatic degradation prevent drugs from reaching the desired site of action [8].

Nanorobots can overcome these limitations by navigating through biological environments and delivering drugs precisely at the target location. These devices are designed to recognize specific cellular markers present on diseased cells. Once the target is identified, the nanorobot releases the therapeutic agent in a controlled manner [9].

Some nanorobots are also designed to respond to environmental signals such as pH changes, temperature variations, or chemical

ISBN 978-816855388-0

gradients. This smart response mechanism enables controlled and site-specific drug release [10].

**4. Clinical Symptoms**

Nanorobot-based drug delivery is mainly used in diseases where precise targeting of drugs is necessary. These diseases often present with severe clinical symptoms that require effective treatment.

Common conditions where targeted drug delivery is beneficial include:

1. **Cancer** – abnormal cell growth leading to tumor formation.
2. **Cardiovascular diseases** – blockage of blood vessels due to plaque accumulation.
3. **Neurological disorders** – degeneration of nerve cells affecting brain function.
4. **Chronic infections** – persistent infections that require targeted antibiotic therapy.

Nanorobots can help reduce the severity of these conditions by delivering drugs directly to the affected tissues [11].

**5. Etiology**

Several factors contribute to the development of diseases that require targeted drug delivery systems. These factors include:

1. **Genetic mutations** leading to abnormal cell growth.
2. **Environmental factors** such as pollution and exposure to toxins.
3. **Lifestyle factors** including unhealthy diet, smoking, and lack of physical activity.

4. **Microbial infections** that cause chronic inflammatory conditions.

Because these diseases often involve complex biological mechanisms, conventional drug delivery methods may not provide effective treatment. Nanorobotic drug delivery systems help overcome these limitations by providing precise and controlled therapy [12].

## 6. Emerging Treatment

Nanorobots represent an emerging and innovative approach in targeted drug delivery. Several types of nanorobotic systems are currently being developed for medical applications.

**Magnetic nanorobots** are controlled using external magnetic fields, allowing precise navigation within the body. **DNA-based nanorobots** are designed to recognize specific molecular signals and release drugs when they detect target cells [13].

Another promising technology involves **biodegradable nanorobots** that break down safely in the body after completing their function. These systems reduce the risk of long-term toxicity and improve patient safety.

Nanorobotic drug delivery has shown potential in cancer therapy, targeted chemotherapy, and gene therapy. These technologies may revolutionize the treatment of many diseases in the future [14].

## 7. Current Research

Current research in nanorobotic drug delivery focuses on improving the design, safety, and efficiency of nanorobots. Scientists are developing advanced nanoscale devices capable of detecting disease markers and delivering drugs with high precision [15].

ISBN 978-816855388-0

Experimental studies have demonstrated the use of DNA nanorobots for targeted cancer therapy. These nanorobots can recognize tumor cells and release anticancer drugs directly at the tumor site.

Researchers are also exploring the integration of artificial intelligence with nanorobotic systems to improve navigation and decision-making capabilities. Although most nanorobotic technologies are still under development, ongoing research suggests that they may soon become an important part of modern medicine.

**References**

[1] Freitas RA. Nanomedicine: Basic Capabilities. Landes Bioscience; 1999.

[2] Torchilin VP. Targeted drug delivery systems. Nature Reviews Drug Discovery. 2005.

[3] Jain KK. Nanotechnology in clinical medicine. Medical Principles and Practice. 2008.

[4] Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery. Drug Discovery Today. 2003.

[5] World Health Organization. Global Cancer Statistics Report.

[6] Peer D et al. Nanocarriers as emerging platforms for cancer therapy. Nature Nanotechnology. 2007.

[7] Brigger I, Dubernet C. Nanoparticles in cancer therapy. Advanced Drug Delivery Reviews. 2012.

[8] Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004.

[9] Cavalcanti A. Nanorobot architecture for medical target identification. Nanotechnology. 2008.

[10] Patra JK et al. Nano based drug delivery systems. Journal of Nanobiotechnology. 2018.

[11] Singh R, Lillard JW. Nanoparticle based targeted drug delivery. Experimental and Molecular Pathology. 2009.

[12] Duncan R. Polymer therapeutics as nanomedicines. Nature Reviews Cancer. 2006.

[13] Douglas SM et al. DNA nanorobots for targeted therapy. Science. 2012.

[14] Zhang L et al. Nanorobotics in medicine. International Journal of Nanomedicine. 2015.

[15] Wang J. Nanomachines: fundamentals and applications. Wiley; 2013.

ISBN 978-816855388-0

# Chapter 12

# Genetic Predisposition in Kidney Stone Disease

**SriRam Chandru.A[a], Krithik.R [a], Ramya.A[b*]**

[a]*Pharm.D, 3rd Year, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai*

[b]*Assistant Professor, Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai*

**Corresponding Author: asriramchandru85@gmail.com*

**Abstract**

Kidney stone disease (nephrolithiasis) affects approximately 10–15% of the global population and is now recognized as a chronic systemic condition with metabolic and cardiovascular implications. Its pathogenesis is multifactorial, involving genetic, metabolic, and environmental factors that drive urinary supersaturation and crystal formation. Heritability estimates of 45–55% underscore the substantial genetic contribution to individual susceptibility. The genetic architecture spans rare monogenic disorders — including primary hyperoxaluria, cystinuria, Dent disease, and Bartter syndrome — and common polygenic susceptibility identified through GWAS, implicating key loci such as CLDN14, SLC34A1, CASR, VDR, and CYP24A1. These variants disrupt fundamental mechanisms including hypercalciuria, hyperoxaluria, hyperuricosuria, reduced urinary citrate, and renal tubular dysfunction. Advances in next-generation sequencing have improved diagnostic precision and enabled genotype-guided management, while pharmacogenomics, RNA interference therapies, and microbiome–genetics interactions

offer emerging avenues for precision medicine. This chapter reviews the genetic basis of kidney stone disease — encompassing monogenic causes, polygenic risk, implicated pathways, and clinical implications — to inform personalized prevention and treatment strategies.

*Keywords: Nephrolithiasis, genetic predisposition, monogenic disorders, GWAS, hypercalciuria, polygenic risk, precision medicine.*

## 1. Introduction

Kidney stones, known in medical terms as nephrolithiasis or urolithiasis, are solid formations that develop in the kidneys from dissolved minerals found in urine. They signify a prevalent urological issue marked by the crystallization of minerals and salts in the kidney system.[1,2] The occurrence of kidney stones is rising globally, impacting around 10–15% of the world's population at some stage in their lives. The condition results in considerable suffering due to pain, urinary blockage, infection hazards, and possible kidney injury.[1]

Nephrolithiasis is a condition defined by the formation of solid crystal-like formations in the urinary region of the kidneys. There is significant diversity in its pathogenesis, risk factors, clinical development, and treatments.[2] Factors that increase the likelihood of people forming kidney stones can be genetic, metabolic, and environmental.[3,4] Nephrolithiasis is now recognized as a sign of systemic illness and a predictor of metabolic and cardiovascular problems.[10]

Systemic conditions, like problems with calcium balance, can increase the risk of developing kidney stones, and rare genetic factors leading to nephrolithiasis are widely recognized.[4] Nonetheless, most KSD cases are classified as idiopathic, with multiple genetic and environmental factors affecting the observed phenotype. The

ISBN 978-816855388-0

homeostatic and renal tubular mechanisms related to these common forms of kidney stone disease are not fully understood, which impedes efforts to develop improved treatment strategies to prevent kidney stone recurrence.[10,15]

Earlier genomic studies suggested that increased serum calcium and decreased serum phosphate levels are likely to heighten the risk of KSD, indicating that minor differences in mineral metabolism within the normal limits may function as a common risk factor for kidney stone formation.[15] As a result, a 0.08 mmol/L increase in serum calcium was linked to a KSD OR of 1.48, whereas a 0.16 mmol/L decrease in serum phosphate levels corresponded to a KSD OR of 1.41.[15] To improve our comprehension of how shifts in calcium and phosphate equilibrium contribute to kidney stone formation, research into genetic discoveries, laboratory experiments, and 3D modeling have been undertaken to pinpoint KSD-related variants associated with diacylglycerol kinase delta (DGKD), solute carrier family 34 member 1 (SLC34A1), and cytochrome P450 family 24 subfamily A member 1 (CYP24A1).[15]

## 2. Heritability of Kidney Stone Disease

Twin and family aggregation studies consistently demonstrate a significant hereditary component to kidney stone disease.[7,9] First-degree relatives of affected individuals face a markedly elevated risk of stone formation, reflecting familial clustering that points to genetic influence, though shared environmental factors may also contribute.[7] Monozygotic twins exhibit higher concordance rates than dizygotic twins, further supporting a heritable basis. Heritability estimates derived from epidemiological data range from 45% to 55%, indicating that genetic factors account for a substantial proportion of

individual susceptibility.[7] These findings underscore the importance of family history in risk assessment and highlight the need for genetic screening and early intervention in high-risk populations.[4,8]

## 3. Types of Kidney Stones and Their Genetic Basis

Kidney stones vary in chemical makeup and are categorized according to their chemical composition.[1,2] Stones that contain calcium are the most prevalent variety. Every type possesses unique genetic, biochemical, and clinical characteristics.[3,4]

### 3.1 Calcium oxalate stones

Calcium oxalate stones make up the largest portion of kidney stones, accounting for 70–80% of them, and usually have a polygenic origin, affected by various genetic variations and environmental influences.[3,4] Stone formation is affected by hypercalciuria, hyperoxaluria, low citrate levels in urine, and acidic urine pH. Genetic influences on calcium and oxalate metabolism are essential.[3,10] In a clinical setting, patients might show symptoms of repeated renal colic and blood in the urine.[1]

### 3.2 Calcium phosphate stones

Calcium phosphate stones can also develop, frequently forming on a calcium phosphate matrix referred to as Randall's plaque. They are infrequent, usually linked to alkaline urine and disorders such as renal tubular acidosis. Genetic variations influencing phosphate regulation and kidney acidification might play a role.

### 3.3 Uric acid stones

Uric acid stones are often associated with genetic elements affecting uric acid metabolism, including variations in the SLC2A9 (which encodes GLUT9) and ABCG2 genes. These stones develop in acidic

ISBN 978-816855388-0

urine and are linked to hyperuricemia, gout, and metabolic syndrome. Genetic susceptibility includes genes that control purine metabolism and kidney acidification. In a clinical setting, uric acid stones might not be visible on X-rays and need targeted diagnostic methods.

### 3.4 Cystine stones

Cystine stones serve as a typical illustration of monogenic kidney stone disorders, caused by mutations in the SLC3A1 and SLC7A9 genes that disrupt amino acid transport within the renal tubules. Cystinuria is a genetic disorder inherited in an autosomal recessive pattern, resulting from mutations in genes that code for renal amino acid transporters, causing reduced reabsorption of cystine and elevated cystine levels in urine. Cystine has low solubility, leading to frequent cystine stones. Cystine stones typically appear during childhood or adolescence and necessitate ongoing management throughout life.

### 3.5 Struvite stones

Struvite stones consist of magnesium ammonium phosphate and are mainly of infectious origin, linked to urinary tract infections caused by urease-producing bacteria. They are typically less associated with direct genetic predisposition, although host immune response genes may influence susceptibility.[1]

### 3.6 Rare Stone Types

Rare stone types include 2,8-dihydroxyadenine stones due to adenine phosphoribosyltransferase (APRT) deficiency and xanthine stones from xanthinuria, both having clear monogenic causes.[5,6] These disorders provide important insights into metabolic pathways of stone formation.[5]

## 4. Genetic Predisposition in Kidney Stone Disease

Genetic predisposition in kidney stone disease refers to inherited factors that increase an individual's susceptibility to forming stones.[4,13] The genetic factors influence essential body functions which include calcium metabolism and oxalate processing together with citrate excretion and renal tubular activity to create conditions that facilitate stone production. The familial clustering of kidney stones demonstrates that this condition has heritable characteristics.[7]

### 4.1 Familial Clustering and Heritability

Epidemiological studies show that first-degree relatives who have kidney stones face significantly higher chances of developing stones themselves.[7,9] The aggregation of this condition within families indicates a genetic basis although shared environmental factors might contribute as well. Twin studies demonstrate heritability because monozygotic twins show higher concordance rates than dizygotic twins.[7]

### 4.2 Gene Variants Affecting Metabolic Pathways

*Calcium Transport Genes*

The genes CLDN14 (claudin-14) and CaSR (calcium-sensing receptor) control the process of calcium reabsorption in the kidneys.[4,15] The presence of mutations or polymorphisms in these genes results in hypercalciuria, which causes excessive calcium loss through urine and represents a significant danger for developing calcium-based kidney stones.[4,10] The body loses control of calcium transport, which results in excessive calcium salt buildup in urine, leading to the development of crystal formation and expansion.[15]

ISBN 978-816855388-0

### 4.3.Oxalate Metabolism Genes

The AGXT gene, which encodes alanine-glyoxylate aminotransferase, contains variants that cause primary hyperoxaluria, a rare autosomal recessive disorder.[5,12] The condition results in higher production of oxalate within the body, which then leads to its excretion through urine, which creates a risk for developing calcium oxalate kidney stones.[5,6] The genes that control oxalate transport and metabolism pathways determine the likelihood of stone formation because they affect the amount of oxalate excreted through urine.[3]

### 4.4.Citrate Transport Genes

Citrate functions as a strong stone formation inhibitor because it binds with calcium to form chemical complexes.[1,10] The genetic changes that affect citrate transporter proteins result in decreased urinary citrate excretion which reduces the protective effects of citrate and raises the likelihood of stone formation.[4]

## 5. Monogenic (Mendelian) Disorders Causing Nephrolithiasis

The group of Mendelian disorders creates KSD, which develops in patients who experience their first symptoms during childhood and show severe disease progression.[5,6] The process of discovering these particular genetic factors establishes the foundation for precise diagnostic assessment and treatment planning.[12] The clinical presentation of these monogenic disorders starts in early life through recurrent stone formation and unique biochemical patterns which require genetic assessment for accurate diagnostic evaluation and treatment planning.[8,13]

### 5.1.Primary Hyperoxaluria

People who have this autosomal recessive disorder develop the condition because of genetic mutations which affect their AGXT (PH1) or GRHPR (PH2) or HOGA1 (PH3) genes. People who have this genetic disorder develop the condition because of an enzymatic defect which causes glyoxylate metabolism to fail. This defect results in their body making too much oxalate which leads to the development of severe calcium oxalate kidney stones.

### 5.2 Cystinuria

The condition occurs through autosomal recessive inheritance because of genetic variants which affect both SLC3A1 and SLC7A9. Patients who have this condition cannot properly absorb cystine along with dibasic amino acids because of genetic mutations which affect their ability to reabsorb these substances.

### 5.3 Dent Disease

The X-linked recessive disorder occurs through mutations which mainly damage CLCN5 and less often affect OCRL. The condition leads to patients experiencing low molecular weight proteinuria together with nephrocalcinosis and hypercalciuria and renal tubular dysfunction and nephrolithiasis.

### 5.4.Bartter Syndrome

The condition consists of a group of renal tubular disorders which follow autosomal recessive inheritance. The disorder causes patients to experience salt wasting and hypokalemia together with nephrocalcinosis and stone formation. The genes which have been mutated in this condition lead to changes in both kidney salt handling and calcium excretion processes.

ISBN 978-816855388-0

Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis

The condition occurs through mutations which affect the CLDN16 and CLDN19 genes. These gene mutations lead to paracellular ion transport deficiencies in the kidney. The deficiency causes patients to lose both magnesium and calcium through their urine.

### *6. Polygenic Risk and Common Variants (GWAS Findings)*

Genome-wide association studies (GWAS) have identified multiple susceptibility loci associated with KSD, including variants near CLDN14, SLC34A1, VDR, and CASR, highlighting the multifactorial nature of common nephrolithiasis.[15] The protective variant rs4293393-T near the UMOD gene, encoding uromodulin, has also been recognized.[16,17] Polygenic risk scores (PRS) derived from these variants offer promise for individual risk stratification and personalized prevention.[15] Furthermore, gene–environment interactions play a significant role, as genetic variants modulate individual responses to dietary and environmental factors in stone disease, including dietary consumption of calcium and oxalate, salt, hydration level, and daily habits, which demonstrate why customized healthcare needs complete solutions.[4,15]

### 7. The genetic basis of kidney stone formation

The genetic basis of kidney stone formation depends on multiple genes that collectively form pathways governing urinary solute concentrations.[4,15] The gene variants which control calcium transport through calcium-sensing receptor (CASR), vitamin D receptor (VDR), vitamin D 24-hydroxylase (CYP24A1), and sodium-phosphate cotransporters SLC34A1/A3 cause disruptions to calcium homeostasis which result in hypercalciuria.[14,15] SLC26A6 functions as an oxalate transporter while AGXT encodes alanine glyoxylate

aminotransferase which together act as vital controllers of oxalate processing and removal.[3,5] SLC2A9 (GLUT9) and ABCG2 together control uric acid transport through their effects on uric acid serum levels and renal excretion which establishes the connection between these factors and uric acid stone development.[15] The FGF23 axis works together with SLC34A1 to handle phosphate management because this system controls phosphate reabsorption and excretion while its disruption results in stone formation.[14] The proteins CLDN14, CLDN16, and TRPM6 function as essential magnesium transport proteins whose dysfunction increases the risk of kidney stone development.[5,15] SLC22A12 (URAT1) functions as a renal tubular transport protein that enables uric acid reabsorption throughout the kidney tubules.[15]

**8. Role of Specific Genetic Variants**

Kidney stone disease (KSD) develops from genetic variants which affect kidney function through two mechanisms: loss-of-function and gain-of-function effects that result in diminished or increased protein activity which subsequently affects stone development.[4,15] The CYP24A1 mutations which encode the enzyme that degrades 1,25-dihydroxyvitamin D lead to vitamin D inactivation impairment which results in idiopathic hypercalciuria and higher KSD risk.[15] Activating mutations in the calcium-sensing receptor (CASR) increase the body's excretion of calcium through urine which leads to increased kidney calcium levels and the development of kidney stones.[4,10] The common genetic variations found in CLDN14 function as one of the most important genetic risk factors that scientists have discovered for calcium stone disease.[15] The presence of a single SLC34A3 variant which causes hereditary hypophosphatemic rickets demonstrates

ISBN 978-816855388-0

that even one genetic change can increase an individual's chances of developing stone disease.[14]

## 9. Conclusion

The genetic components of kidney stone disease include three categories which are unique monogenic disorders and widespread polygenic risk factors and complex interactions between genes and environmental factors.[4,5,15] Genetic testing should become part of medical practice because it helps doctors make correct diagnoses and assess patient risk while creating tailored treatment plans which show how kidney stone disease has progressed from being seen as a urological condition to becoming recognized as a permanent systemic illness.[12,13] The field has made progress through GWAS discoveries and monogenic classification work yet fundamental knowledge gaps continue to exist about how common genetic variants increase disease risk.[15] The main research objectives will focus on conducting extensive genomic research and validating genetic variants through functional studies and connecting genomics with epigenomics and metabolomics and microbiome research to develop personalized medical treatments.[4,15]

## References

[1] F. Tamborino et al., "Pathophysiology and Main Molecular Mechanisms of Urinary Stone Formation and Recurrence," International Journal of Molecular Sciences, vol. 25, no. 5. MDPI AG, p. 3075, Mar. 06, 2024. doi: 10.3390/ijms25053075.

[2] F. L. Coe, "Kidney stone disease," Journal of Clinical Investigation, vol. 115, no. 10. American Society for Clinical Investigation, pp. 2598–2608, Oct. 01, 2005. doi: 10.1172/jci26662.

[3] H. O. Goodman, R. P. Holmes, and D. G. Assimos, "Genetic Factors in Calcium Oxalate Stone Disease," Journal of Urology, vol. 153, no. 2.

Ovid Technologies (Wolters Kluwer Health), pp. 301–307, Feb. 1995. doi: 10.1097/00005392-199502000-00003.

[4] G. Gambaro et al., "Genetics of hypercalciuria and calcium nephrolithiasis: From the rare monogenic to the common polygenic forms," American Journal of Kidney Diseases, vol. 44, no. 6. Elsevier BV, pp. 963–986, Dec. 2004. doi: 10.1053/j.ajkd.2004.06.030.

[5] F. Assawi and T. Faghihi, "A narrative review of monogenic disorders causing nephrolithiasis and chronic kidney disease," Nephrology, vol. 29, no. 12. Wiley, pp. 781–790, Nov. 05, 2024. doi: 10.1111/nep.14373.

[6] D. A. Braun et al., "Prevalence of Monogenic Causes in Pediatric Patients with Nephrolithiasis or Nephrocalcinosis," Clinical Journal of the American Society of Nephrology, vol. 11, no. 4. Ovid Technologies (Wolters Kluwer Health), pp. 664–672, Apr. 2016. doi: 10.2215/cjn.07540715.

[7] J. C. Lieske et al., "Heritability of Urinary Traits That Contribute to Nephrolithiasis," Clinical Journal of the American Society of Nephrology, vol. 9, no. 5. Ovid Technologies (Wolters Kluwer Health), pp. 943–950, May 2014. doi: 10.2215/cjn.08210813.

[8] A. M. Gefen and J. J. Zaritsky, "Review of childhood genetic nephrolithiasis and nephrocalcinosis," Frontiers in Genetics, vol. 15. Frontiers Media SA, Mar. 28, 2024. doi: 10.3389/fgene.2024.1381174.

[9] L. L. Strate et al., "Heritability and Familial Aggregation of Diverticular Disease: A Population-Based Study of Twins and Siblings," Gastroenterology, vol. 144, no. 4. Elsevier BV, pp. 736–742, Apr. 2013. doi: 10.1053/j.gastro.2012.12.030.

[10] T. Arcidiacono et al., "Idiopathic Calcium Nephrolithiasis: A Review of Pathogenic Mechanisms in the Light of Genetic Studies," American Journal of Nephrology, vol. 40, no. 6. S. Karger AG, pp. 499–506, 2014. doi: 10.1159/000369833.

[11] P. Goodyer et al., "Cystinuria subtype and the risk of nephrolithiasis," Kidney International, vol. 54, no. 1. Elsevier BV, pp. 56–61, Jul. 1998. doi: 10.1046/j.1523-1755.1998.00957.x.

ISBN 978-816855388-0

[12] M. C. Breeggemann et al., "The Evolving Role of Genetic Testing in Monogenic Kidney Stone Disease: Spotlight on Primary Hyperoxaluria," Journal of Urology, vol. 212, no. 5. Ovid Technologies (Wolters Kluwer Health), pp. 649–659, Nov. 2024. doi: 10.1097/ju.0000000000004147.

[13] M. A. Anderegg et al., "Prevalence and characteristics of genetic disease in adult kidney stone formers," Nephrology Dialysis Transplantation, vol. 39, no. 9. Oxford University Press (OUP), pp. 1426–1441, Mar. 27, 2024. doi: 10.1093/ndt/gfae074.

[14] D. Dasgupta et al., "Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis," Journal of the American Society of Nephrology, vol. 25, no. 10. Ovid Technologies (Wolters Kluwer Health), pp. 2366–2375, Oct. 2014. doi: 10.1681/asn.2013101085.

[15] C. E. Lovegrove et al., "Genetic variants predisposing to an increased risk of kidney stone disease," Journal of Clinical Investigation, vol. 135, no. 15. American Society for Clinical Investigation, May 15, 2025. doi: 10.1172/jci186915.

[16] D. F. Gudbjartsson et al., "Association of Variants at UMOD with Chronic Kidney Disease and Kidney Stones—Role of Age and Comorbid Diseases," PLoS Genetics, vol. 6, no. 7. Public Library of Science (PLoS), p. e1001039, Jul. 29, 2010. doi: 10.1371/journal.pgen.1001039.

[17] Y. Tanaka et al., "IP06-14 Cooling-Induced Brushite Crystals As A Novel Biomarker For Predicting Calcium Oxalate Stone Recurrence," Journal of Urology, vol. 213, no. 5S. Ovid Technologies (Wolters Kluwer Health), May 2025. doi: 10.1097/01.ju.0001109820.51058.5a.14.


ISBN 978-816855388-0

# Innovations in Pharmaceutical Therapeutics and Drug Delivery

## April 2026

**Dr.A.Ramya** is an Assistant Professor in the Department of Pharmacology at the School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, located in Chennai. She has extensive professional experience in both hospital practice and academic teaching within the pharmacy sector. With over 8 years of teaching experience, she has been actively involved in educating pharmacy students and contributing to academic development. Her teaching expertise includes subjects such as Clinical Pharmacy, Human Anatomy and Physiology, Toxicology, and Pathophysiology.

**Mrs. R. Prasidha** is an Assistant Professor in the Department of Pharmaceutical Chemistry and Analysis with 5.5 years of teaching and research experience. Completed B.Pharm and M.Pharm at Sri Ramakrishna Paramedical Sciences, College of Pharmacy, Coimbatore, and is currently pursuing a Ph.D at Vels Institute of Science and Technology. Published three research articles, including one indexed in Scopus, along with three book chapters, and holds three patents. Research interests include drug design and development and synthetic chemistry. Possesses expertise in handling advanced analytical instruments such as HPLC, UV, IR, and GC, contributing to academic and research excellence.

**Dr. Vijayakumar Murugesan** He is an experienced professional in technology transfer, holding a Master's degree in Pharmacy from BITS Pilani. With over 19 years of expertise, he has significantly contributed to Research & Development and technology transfer, particularly in the area of cancer drug formulations. His core competencies include process optimization, scale-up, and ensuring regulatory compliance, facilitating a seamless transition from development to commercialization. Currently pursuing a Ph.D. in Regulatory Affairs, specializing in cosmetics, he is deepening his understanding of global regulatory standards. He is also actively engaged in pioneering research focused on advancing cancer drug formulations, with a strong emphasis on enhancing efficacy, safety, and patient outcomes.

**Dr. Kommu Pradeep,** Assistant Professor at Villa College, Maldives, has over 13 years of experience in pharmaceutical sciences. He has published 20+ research papers, authored 4 textbooks, and holds 6 patents. He earned his M.Pharm. from JNTU, Kakinada, a Ph.D. in Pharmaceutical Sciences from Acharya Nagarjuna University, and a Postgraduate Certificate in Teaching in Higher Education (PCTHE) from Villa College. Additionally, he holds an MBA in Human Resource Management. Dr. Pradeep has supervised 20 postgraduate and 75 undergraduate students and is a lifetime member of IPGA and APTI.


**SCIENTIFIC RESEARCH REPORTS**

(A Book Publisher, approved by Govt. of India)

I Floor, S S Nagar, Chennai - 600 087,
Tamil Nadu, India.
editors@srrbooks.in, contact@srrbooks.in
www.srrbooks.in

ISBN 978-81685538-8-0